Category: ACN Newswire

Susan Rohac, ICD.D, built one of Canada's largest and most active climate funds, overseeing a Pan-Canadian team of investment professionals and managed a portfolio over $1 billion in assets.Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 18, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the appointment of Mrs. Susan Rohac, ICD.D, to its Board of Directors, effective immediately. Mrs. Rohac replaces long-serving director Robin Dow, who has stepped down from the Board to focus on personal pursuits and other interests, and will continue to support a smooth transition.Susan Rohac had an extensive thirty-four (34) plus year career at the Business Development Bank of Canada ("BDC"), holding various leadership roles. Her final role was as Managing Partner of the Climate Tech venture capital fund, which she held from 2017 to May 2025. In this role, she oversaw a pan-Canadian team of investment professionals and managed a portfolio of over $1 billion in assets. This portfolio included a fully deployed $600 million fund I and a $500 million fund II launched in 2022 that focused on investing in Canada's most promising clean technology companies. Susan has invested in a diverse range of climate technologies across various sectors, including energy, mobility, built environment, carbon management, and industry & resource space, including advanced materials and critical minerals. In 2024, Susan was recognized as a Climate Leader by the Clean50 and received the Clean16 award. She holds undergraduate degrees in both science and finance and an executive MBA from the University of Ottawa. In 2024, she also obtained her ICD.D governance designation from the University of Toronto. Passionate about the environment and climate technologies, Susan currently sits on several governance and advisory boards and is actively involved with a few organizations that are aligned with her interests."We are delighted to welcome Susan to our Board," said Jeff York, Founder and Chairman of Focus Graphite. "She brings a strong track record in corporate finance and scaling industrial technologies, with a deep appreciation for Canada's critical minerals opportunity. Her experience and connections in the industry will be invaluable.""I am honored to join Focus Graphite at such an important moment," said Ms. Rohac. "The shift to green energy is driving unprecedented demand for secure supplies of critical minerals, and Canada has an opportunity to lead in building a reliable, sustainable graphite supply chain here at home. Beyond batteries, graphite is essential for advanced manufacturing and defense applications that underpin national security. I look forward to working with the team to help strengthen North America's self-sufficiency and reduce reliance on foreign supply."Mr. York added, "On behalf of the company and our shareholders, I want to thank Robin for his years of service and leadership. His guidance helped position Focus for its next phase of growth."Focus Graphite is also pleased to announce its participation in the Canadian Critical Minerals Investment Forum, an international trade mission organized by Natural Resources Canada and Invest in Canada. The event will be held in Tokyo, Japan from August 26-28, 2025, and in Korea from August 29-30, 2025. Focus Graphite is one of only two Canadian graphite companies attending the Forum, which brings together global investors, government officials, and industry leaders to advance critical minerals partnerships. In addition to the Forum, the Company will hold a series of bilateral meetings in both countries to further strategic discussions with potential partners and customers.On August 14th, 2025, Focus Graphite visited its Lac Knife project site near Fermont, Québec. The Company was pleased to host a representative from Korea Mine Rehabilitation and Mineral Resources Corporation ("KOMIR") alongside its newest board member, Susan Rohac. During the visit, Focus also met with officials from the Town of Fermont to provide a corporate and project update, highlighting recent progress and outlining the Company's pathway toward advancing Lac Knife to a fully permitted mining operation.In connection with Ms. Rohac's appointment, the Company has granted her 250,000 stock options pursuant to its Stock Option Plan. The options are exercisable at a price of $0.35 per common share and will expire on August 17, 2030. They are subject to the terms of the Plan as well as the policies of the TSX Venture Exchange.Image 1: Focus Graphite executives, IOS Geosciences, and a representative from KOMIR visit the Lac Knife project near Fermont, Québec, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_001full.jpgImage 2: Focus Graphite executives and IOS Geosciences visit with representatives from the Town of Fermont, QC, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_002full.jpgAbout Invest in CanadaInvest in Canada is Canada's foreign direct investment (FDI) attraction and promotion agency. We find the best to invest in Canada. This means working with our partners across the country and worldwide to attract global companies and support their expansion plans in Canada.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the advancement of the Lac Knife project through permitting and development activities, the Company's participation in the Canadian Critical Minerals Investment Forum in Japan and Korea and the potential outcomes of related bilateral meetings, the anticipated benefits of Ms. Rohac's appointment to the Board of Directors, the Company's ability to establish strategic partnerships and secure future customers, and its positioning as a near- and long-term supplier of specialty graphite materials within North America and globally.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262819 Copyright 2025 ACN Newswire via SeaPRwire.com.

Development Highlights- During the reporting period, the Group had two innovative products approved for marketing by the NMPA, namely Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection).- In the first half of 2025, the Group’s sales of innovative products reached RMB7.8 billion, a year-on-year increase of 27.2%. In addition to innovative products, the Group had 5 generic drugs approved for marketing by the NMPA. The overall revenue of generic drugs achieved positive growth in the first half of 2025.- As of 30 June 2025, the Group had a total of 37 innovative drug candidates in the field of oncology, 7 innovative drug candidates related to liver/metabolic diseases, 13 innovative drug candidates related to the respiratory, and 6 innovative drug candidates in the field of surgery/analgesia in the process of clinical trial application or above. Of these, 2 innovative oncology drug candidates and 1 innovative surgery/analgesia drug candidate are in the marketing application stage, and 11 innovative oncology drug candidates, 1 innovative liver/metabolic diseases drug candidate, 3 innovative respiratory system drug candidates, and 1 innovative surgery/analgesia drug candidate are in Phase III clinical trials. In addition, the Group had a total of 13 biosimilar or generic drug oncology candidates, 6 additional biosimilar or generic liver/metabolic diseases drug candidates, 12 biosimilar or generic respiratory system drug candidates, and 6 biosimilar or generic surgical/analgesic drug candidates in the clinical trial application or above.- Focus V (Anlotinib Hydrochloride Capsules) is a new type of small molecule multi-target tyrosine kinase inhibitor. It has been approved for nine indications, and three other indications are currently in the marketing application stage. In addition, Anlotinib has a number of new indications currently in Phase III clinical studies, including first-line non-squamous non-small cell lung cancer and first-line pancreatic cancer, with plans to gradually submit marketing applications within the next two years.- From 2023 to 2024, the Group obtained approval for and launched a total of five national category 1 innovative oncology drugs, namely, Yilishu (Efbemalenograstim alfa Injection), Andewei (Benmelstobart Injection), Anboni (Unecritinib Fumarate Capsules), Anluoqing (Envonalkib Citrate Capsules), and Anfangning (Garsorasib Tablets). It also obtained approval for and launched 4 oncology biosimilars, including Anbesi (Bevacizumab Injection), Delituo (Rituximab Injection), Saituo (Trastuzumab Injection), and Paletan (Pertuzumab Injection). The sales volume of these products accelerated rapidly in the first half of 2025, and they have become important contributors to the Group’s revenue growth.- Lanifibranor (pan-PPAR agonist) is an orally available small molecule drug that is currently undergoing Phase III clinical trials worldwide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and enrollment of the patients in the global main cohort has been completed. In July 2023, Lanifibranor was granted Breakthrough Therapy Designation by the CDE. Lanifibranor is China’s first MASH drug to enter Phase III clinical trials and is expected to fill the gap in China’s MASH market.- Tianqing Suchang (Budesonide Suspension for Inhalation) is China’s first budesonide nebulized generic drug approved for marketing, breaking the long-term monopoly of branded drugs in the domestic market, and offering an effective, safe and economical high-end product for patients with chronic airway inflammation in China. The product has been included in the national VBP. The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the VBP.- Zepolas/Debaian (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. The Group focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand, driving the sustained rapid sales growth of Zepolas/Debaian. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. By upgrading the dosage form, the second-generation product can significantly improve the transdermal absorption of the drug and enhance the adhesiveness of the plaster, thereby improving patient compliance.HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX stock code:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2025 (the “Period”).During the Period, the Group recorded revenue of approximately RMB17.57 billion, a year-on-year increase of approximately 10.7%. Profit attributable to owners of the parent from continuing operations as reported was approximately RMB3.39 billion, a year-on-year increase of approximately 140.2%. Earnings per share attributable to owners of the parent were approximately RMB18.82 cents. The significant year-over-year increase in profit attributable to owners of the parent from continuing operations was mainly driven by the notable growth in revenue and significant increase in dividend income and fair value gain on investments during the Period. Underlying profit attributable to owners of the parent (non-HKFRSs measure) was approximately RMB3.09 billion, a YOY increase of approximately 101.1%. The Group's liquidity remains strong, with cash and bank balances classified as current assets of approximately RMB11.1 billion, bank deposits classified as non-current assets of approximately RMB10.1 billion, and wealth management products of approximately RMB9.29 billion in total, and total fund reserves amounting to approximately RMB30.49 billion at the end of the Period.The Board of Directors has recommended an interim dividend payment of HK5 cents per share (1H2024: HK3 cents).Sales: Strong momentum in R&D innovation with volume growth across multiple fieldsAlways placing utmost importance on research and development (“R&D”), the Group has consistently increased investments to enhance R&D quality and efficiency, which has led to a marked strengthening of R&D capabilities, driving sustained sales revenue growth and delivering substantial results. During the Period, sales of oncology drugs increased by 24.9% year-on-year to approximately RMB6.69 billion, accounting for approximately 38.1% of the Group's revenue. Sales of surgical/analgesic medications increased by 20.2% year-on-year to approximately RMB3.11 billion, accounting for approximately 17.7% of the Group's revenue.In the field of oncology, the Group has a comprehensive layout in non-small cell lung cancer (NSCLC), covering the full-line treatment of multiple subtypes. The EGFR/cMet bispecific antibody TQB2922 is about to initiate a Phase III clinical trial for second-line NSCLC, while the EGFR/cMet bispecific antibody ADC TQB6411 is currently enrolling patients for its Phase I trial, with both products progressing at the forefront in China. Also, the Group is deeply invested in the three major subtypes of breast cancer. The CDK2/4/6 inhibitor “Culmerciclib Capsule (TQB3616)” has the potential to become a best-in-class (BIC) therapy for HR+/HER2- breast cancer. The HER2 bispecific ADC TQB2102 demonstrates potentially superior safety compared to DS-8201, with multiple indications being explored simultaneously, including three breast cancer Phase III trials advancing rapidly. Additionally, the Group has systematically targeted key gastrointestinal cancers such as colorectal, gastric, pancreatic, and liver cancers. LM-108 (CCR8 monoclonal antibody) and TQB2868 (PD-1/TGF-β bifunctional fusion protein) are progressing at the fastest pace globally, with current clinical data showing significant potential.In the field of surgery/analgesia, the Group continuously focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand. During the Period, the Group drove the sustained rapid sales growth of Zepolas, and the second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. Meanwhile, Putanning, which was approved in May 2025, is expected to become a new growth driver in this field due to its strengths, such as long-acting analgesia and excellent safety.R&D: Fully Committed to Advancing Innovative Product Development with Enhanced R&D InvestmentDuring the reporting period, the Group had two innovative products approved for marketing by the NMPA, namely Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection). In the first half of 2025, the Group’s sales of innovative products reached RMB7.8 billion, a year-on-year increase of 27.2%. In addition to innovative products, the Group had 5 generic drugs approved for marketing by the NMPA. The overall revenue of generic drugs achieved positive growth in the first half of 2025.The Group has always placed the utmost importance on R&D, continuously improving its R&D capabilities and speed. It considers R&D the foundation for its sustainable development and has continuously increased its investment in R&D. For the six months ended 30 June 2025, R&D costs amounted to approximately RMB3,187.56 million, representing approximately 18.1% of the Group’s revenue. Including capitalised R&D expenditure, approximately 95.7% was recognised in the statement of profit or loss.Prospect: Deepening Innovation and Global Expansion to Accelerate the Building of Global Pharmaceutical Innovation CompetitivenessChina’s pharmaceutical industry is currently embracing historic growth opportunities. With the national strategy of innovation-driven development as the guidance, the country’s biopharmaceutical innovation capabilities have witnessed significant enhancement, such that the R&D of innovative drugs has evolved from the positioning of the “passive mover” towards the “paralleled player,” or even the “market leader” on the global stage. Chinese innovative drugs not only gains strong momentum for growth in the domestic market, but also steadily makes their presence internationally, thus being widely recognized and becoming an indispensable impetus in the innovative pharmaceutical industry worldwide. As the industry leader, the Group remains deeply committed to four core therapeutic areas – oncology, liver/metabolic diseases, respiratory diseases, and surgery/analgesia. The Group aims to be a leading global pharmaceutical company through delivering innovative therapies for patients.While being firmly rooted in the Chinese market, the Group is expanding its strategic horizon to embrace global opportunities, and leveraging internationalization to accelerate its innovation and development. In the meantime, the Group is vigorously promoting its global strategic collaboration deployments through diversified approaches of collaborations such as business development (BD), strategic acquisitions, etc. In July 2025, the Group announced the full acquisition of LaNova Medicines. LaNova Medicines boasts world-leading antibody discovery and ADC technology platforms, including the Tumor Microenvironment Specific Antibody Development Platform (LM-TME™), the Targeted Antibody Discovery Platform (LM-Abs™), the New Generation ADC Platform (LM-ADC™), and the T-cell Engager Platform (LM-TCE™). The acquisition will further enhance the Group's innovative R&D capabilities and accelerate the growth of the Group's innovative business. In addition, the LaNova Medicines’ outstanding and efficient R&D team will join the Group to further strengthen its innovation and R&D talent pool, ensuring the sustained delivery of high-quality innovation outcomes, and supporting the long term development of the Group’s innovation ecosystem.Looking ahead, the Group will remain focused on innovation, while enhancing R&D efficiency and quality across its four major therapeutic areas. The Group will also accelerate its progress of internationalization, thereby striving for rapid business expansion alongside steady performance improvement.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited is a leading Chinese pharmaceutical company continuing to invest in Oncology, Liver/Metabolic Diseases, Respiratory and Surgery/Analgesia, exploring innovative therapies to improve the lives of patients. The company has strong manufacturing capabilities and broad patient access across China. Sino Biopharmaceutical Limited is committed to bring innovation to address unmet healthcare needs globally. The company was listed on the Hong Kong Stock Exchange in 2000, and was selected as a component of the MSCI Global Standard Index in China in 2013; In 2018, it was selected as a constituent stock of Hang Seng Index; In 2020, it was selected as a constituent stock of Hang Seng Stock Connect Biotech 50 Index and the Hang Seng China (Hong Kong Listed) 25 Index. The company has been listed in the “Top 50 Global Pharmaceutical Enterprises” published by the authoritative American magazine Pharmaceutical Manager for seven consecutive years, and has been rated as the “Top 50 Best Companies in Asia Pacific” by Forbes (Asia) for three consecutive years.For more information, please visit: www.sinobiopharm.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Global leading storage battery company in data center and telecom industries – Shuangdeng Group Co., Ltd. (stock code: 06960.HK), proposes to list its H Shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).Shuangdeng Group plans to offer 58,557,000 H Shares (subject to the Over-allotment Option), of which 52,701,000 H Shares will be International Offer Shares (subject to reallocation and the Over-allotment Option), representing approximately 90% of the initial offer shares; the remaining 5,856,000 H Shares will be Hong Kong Offer Shares (subject to reallocation), representing approximately 10% of the initial offer shares. The Offer Price is HK$14.51 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Hong Kong Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund).Shuangdeng Group will open for Hong Kong Public Offering in Hong Kong at 9 a.m., August 18, 2025 (Monday), and close at 12:00 noon, August 21, 2025 (Thursday). Dealings in H shares of Shuangdeng Group on the Main Board of the Hong Kong Stock Exchange is expected to commence on August 26, 2025 (Tuesday). The H shares will be traded in board lot of 500 H shares each. The Company’s stock code will be 06960.HK.China International Capital Corporation Hong Kong Securities Limited, Huatai Financial Holdings (Hong Kong) Limited and CCB International Capital Limited are Joint Sponsors, Sponsor-Overall Coordinators, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Mangers. Sanshui Venture Capital Co., Limited is the cornerstone investor, subscribing for H shares worthing approximately RMB220 million in total.Global leading storage battery company in data center and telecom industriesFounded in 2011 in Taizhou, Jiangsu Province in China, Shuangdeng Group is a leading company in energy storage business for big-data and telecommunication industries. With a deep understanding of the industry and customer demand, Shuangdeng Group has developed industry-leading technologies and multi-pathway products with optimal balance among safety, cost efficiency and performance, which enables it to capture huge growth potential in its industry. According to Frost & Sullivan, in 2024, the Company ranked the first among global telecom base station and data center energy storage battery providers in terms of shipment volume, achieving a market share of 11.1%.With its unwavering commitment to enhance the market recognition of its brand, Shuangdeng Group boast a high-quality global customer base with nearly 30 of the world’s top 100 telecom operators and equipment manufacturers, forging strong relationship with leading telecom operators and telecommunication equipment manufacturers in China, such as China Mobile, China Telecom, China Unicom, and China Tower, as well as prominent international telecommunication giants like Ericsson, Vodafone, Orange, and Telenor. In addition, as of December 31, 2024, Shuangdeng Group served 80% of top 10 Chinese self-owned data center companies and 90% of top 10 Chinese third-party data center companies.R&D capabilities in high safety, cost efficiency and superior performanceShuangdeng Group’s products span diverse application scenarios, including energy storage for telecom base stations, data centers, and the electrical energy storage settings. Shuangdeng Group continuously expand its technology portfolio to encompass lithium-ion batteries, lead-acid batteries, sodium-ion batteries, and solid-state batteries, ensuring it can provide the most suitable products for various application scenarios and diverse customer use. Its R&D efforts are focused on addressing the needs and pain points of customers operating telecom base stations and data centers, with a steadfast commitment to ongoing improvements in safety, cost, and performance of products.Shuangdeng Group has established a technical expert committee led by multiple academicians and comprised of over 30 renowned industry experts. This committee collaborates with distinguished experts from leading institutions such as China Electric Power Research Institute, Tsinghua University, Nanjing University, and Huazhong University of Science and Technology. Together, the Company has developed a long-term, stable research and communication mechanism, regularly engaging in academic exchanges to stay abreast of cutting-edge technological advancements. Through active collaboration between industry, academia, and research, Shuangdeng Group continuously optimizes its product manufacturing process and technologies, driving ongoing innovation. As of August 8, 2025, the Company held a total of 353 patents, including 111 invention patents.Data center business accelerates, emerging as a key growth driverWith the penetration and promotion of big data, technologies, energy storage batteries for data centers have become essential products for ensuring data security and energy security. In 2018, Shuangdeng Group keenly identified the market demands of the internet era and began establishing cooperation relationship with large tech companies and data center operators. Since 2018, the Company has successively collaborated with Alibaba, JD.com, Baidu, GDS, and ChinData. In 2022, Shuangdeng Group innovatively developed the first large-scale dual-function energy storage plan incorporating “backup power + power storage and management” for data centers in China, and supplied our products to the Xiong’an Urban Supercomputing Center, contributing its successful achievement of being recognized as national green data center. Up to August 8, 2025, its energy storage products have been used in hundreds of data centers.According to Frost & Sullivan, in 2024, Shuangdeng Group ranked first among Chinese companies in terms of shipment volumes in the global data center energy storage market and its market share in the global data center market reached 16.1%. Revenues from sales of batteries used in data centers increased by 120% YoY from RMB397.0 million in the five months ended May 31, 2024 to RMB872.9 million in the five months ended May 31. This expansion boosted its contribution to total revenue from 28.4% to 46.7%, making it the company’s largest revenue source. Driven by the increase in revenues from sales of batteries used in data centers, the Company’s total revenues increased from RMB1,394.2 million in the five months ended May 31, 2024 to RMB1,866.6 million in the five months ended May 31, 2025.An experienced and visionary management teamShuangdeng Group is led by a visionary, stable, and highly experienced management team. The Company’s Chairman, Dr. Yang Rui, brings extensive experience in the energy storage battery industry and a global perspective. He has been honored with multiple accolades, including the 2024 Person of the Year in Energy Storage Battery Industry, and Jiangsu Province Excellent Entrepreneur. His forward-thinking strategic decisions have driven the Company’s continuous innovation and growth. Its executive Director and deputy general manager, Dr. Yang Baofeng, is a senior engineer who has received distinguished honors, such as ‘‘Jiangsu Province Technology Entrepreneur’’ and ‘‘Innovation and Entrepreneurship Star.’’ He also serves as Vice Chairman of the China Battery Industry Association and the China Chemical and Physical Power Industry Association. Its senior management team possesses deep expertise in energy storage battery technology and business management. All senior team members have been with us for many years, ensuring effective management collaboration and a unified long-term business strategy.Dr. Yang Rui, Chairman of the Board, Executive Director and Chief Executive Officer of Shuangdeng Group said, “As a global leading storage battery company in data center and telecom industries, we always adhere to our customer-centric approach and devote ourselves to delivering the most suitable and premium batteries to our customers across various industries, including telecom operators and tech companies. As artificial intelligence technology ushers in a new era of widespread adoption, the surging demand for computing power will drive unprecedented growth in energy needs. In response to the expanding demand for computing power and the increasing energy consumption of data centers, we will maintain our innovative drive to seize growth opportunities in the data center sector and cultivate our second growth pillar. Meanwhile, we will continue to deepen our presence and penetration in existing markets while expanding our global presence, further strengthening our position as a globally leading brand.”Use of ProceedsShuangdeng Group estimates that it will receive net proceeds from the Global Offering of approximately HK$756.3 million, assuming the Over-Allotment Option is not exercised, after deducting the underwriting fees and commissions (assuming the full payment of the discretionary incentive fee) and estimated expenses payable by the Company. Approximately 40.0%, or approximately HK$302.6 million, will be used for the construction of a lithium-ion batteries production facility in Southeast Asia. Approximately 35.0% or approximately HK$264.7 million, is intended to be used to fund the establishment of a research and development center. Approximately 15.0%, or HK$113.4 million, is intended to be used to strengthen its overseas sales and marketing so that the Company can enhance its global presence, better serve its overseas customers and boost its international sales. And approximately 10%, or HK$75.6 million, will be used to provide funding for working capital and other general corporate purposes.For further information, please contact:Porda Havas International Finance Communications GroupMs. Kelly Fung+852 3150 6763kelly.fung@h-advisors.globalMs. May Yang+86 21 3397 8725may.yang@h-advisors.global Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - uSMART Securities, a strategic investment of Chow Tai Fook (Holding) Limited, is pleased to announce the official launch of its new branches at Hong Kong’s Lok Ma Chau MTR Station and West Kowloon High-Speed Rail Station, strategically positioned to serve cross-border clients and passengers. A grand opening ceremony was held at the West Kowloon branch, attended by prominent financial professionals.At the event, Mr. Neo Lee, Executive Director of uSMART Securities, stated: "To provide more accessible financial services, uSMART Group plans to open 12 service centers across Hong Kong and Singapore this year, covering key districts such as Tsim Sha Tsui, Causeway Bay, Tsuen Wan, Sheung Shui, and Sheung Wan. This expansion will enhance our regional service network and bring us closer to our local clients."“As a No.1 Hong Kong Funded Fintech Brokerage^ with over 800,000 users globally, uSMART Securities is committed to elevating the investment experience. Our new branches offer comprehensive services, including investment consultations, account opening assistance, and personalized support for seniors and beginners to navigate our trading app," added Neo Lee.(From left to right: Business Development Director of uSMART Securities, Marketing Director of uSMART Securities, Executive Director of uSMART Securities, Head of Research and Asset Management of uSMART Securities and Business Development Manager of uSMART Securities)During the launch period, clients can enjoy exclusive mystery gift upon check in new shop, along with complimentary beverages, and mobile charging services. New customers who open an account at the branch will receive additional rewards. To further penetrate the Hong Kong market, uSMART Securities has introduced its "Trader Account", offering lifetime 0 commission for US and HK Stocks, plus 0 commission for US options trading for local clients.As a token of appreciation, uSMART Securities is rolling out a suite of 0 fee promotions for both new and existing clients, including:1)0% margin interest for IPO subscriptions | 0 handling fees for cash subscriptions2)0 commission & 0 platform fees for 100+ Hong Kong ETFs (covering high-dividend, virtual asset, and index ETFs)3)$0 cost to invest in US & HK stocks Monthly Investment Plan (no commission, platform fee, custody fee, and dividend collection fee)These offers are designed to support investors with different short, medium, and long-term investment strategies, ensuring all uSMART Securities clients could enjoy.Neo Lee also revealed that uSMART Group is actively expanding its teams in Hong Kong and Singapore to strengthen competitiveness. The Group’s newly established Manhattan office in New York will focus on serving hedge funds, family offices, and pre-IPO companies with institutional brokerage, asset allocation, and investment banking advisory services, reinforcing its leadership in fintech brokerage.Moving forward, uSMART Securities remains dedicated to customer-centric innovation, delivering premium offline services and cutting-edge financial solutions for global investors.^”No.1 Hong Kong Funded Fintech Brokerage" is based on TradeGo Cloud data, with uSMART Securities ranking first in monthly transaction volume among local Hong Kong-funded internet brokers for over a year as of May 2025.Terms and conditions apply.About uSMART:Strategic investments from Chow Tai Fook (Holding) Limited, uSMART Securities is a leading Hong Kong Funded Fintech Brokerage founded in 2018. Over the past seven years, it has pioneered the fusion of technology and finance, offering stocks trading, asset management, and wealth management solutions. Its proprietary platforms, uSMART HK APP and uSMART SG APP, operated by uSMART Securities (Hong Kong) and uSMART Securities (Singapore) respectively. It supports investments in Hong Kong stocks, US stocks, A-shares (Shanghai,Shenzhen,and Hong Kong stock connect), Singapore Stocks, Japan Stocks, UK Stocks, US options, ETFs, Funds, Bonds, Asset Management, Structured Notes, Futures, Crypto, Precious Metals, Gold, and forex. Furthermore, uSMART is equipped with a highly professional research and asset management team that offers asset management, wealth management, securities brokerage, institutional business, LPF services, and investment banking, dedicated to serving ultra-high-net-worth individuals and families, corporations, investment institutions, fund companies, and other brokerage firms with comprehensive asset management solutions.For details please visit: https://hk.usmartglobal.com/For any media queries, please contact:Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - On August 17, 2025, the inaugural World Humanoid Robot Games—an international event centered on humanoid robots—concluded successfully at the National Speed Skating Oval in Beijing, also known as the “Ice Ribbon.”Co-hosted by the Beijing Municipal Government, China Media Group, the World Robot Cooperation Organization, and the Asia-Pacific RoboCup Council, the Games gathered 280 teams and over 500 robots from around the globe to compete across 26 disciplines, showcasing the full industrial chain from technological breakthroughs to real-world applications in embodied intelligence.As a key industrial accelerator, Shoucheng Holdings (0697.HK) saw several of its portfolio companies participate in major events, collectively winning 37 medals (12 gold, 14 silver, and 11 bronze), including awards where teams utilized robots built by Shoucheng’s portfolio firms. Simultaneously, Shoucheng launched the "Shoucheng Robot Tech Experience Store" adjacent to the venue, which became one of the most visited tech exhibits of the event.Highlights from Portfolio Companies:Unitree Robotics captured 4 gold medals and achieved a top speed of 4.78 m/s; G1-based teams earned an additional 1 gold, 1 silver, and 1 bronze;Beijing Humanoid Robot Innovation Center won 2 gold, 6 silver, and 2 bronze, representing the most advanced “fully autonomous execution” capabilities;Noetix Robotics earned 2 gold, 1 silver, and 1 bronze in gymnastics, long jump, and dance events, becoming a standout in “Tech × Art” integration;Galbot (by Galbot Technologies) secured the autonomous sorting championship and supported university teams that swept the podium;Galaxea-AI served as exclusive hardware provider in scene-based competitions and enabled a third-place finish by Beihang University;Booster Robotics powered all 3V3 and 5V5 football events, providing robot hardware and technical support, and was deemed the “backstage champion.”Robot Tech Experience Store: Bringing Innovation to the EverydayDuring the event, Shoucheng launched a pop-up “Robot Tech Experience Store,” featuring over 200 smart products across home, education, entertainment, healthcare, and wearables. The official store will open during China’s National Day Golden Week in October 2025 at Fusion Stone Plaza, Beijing, with nationwide expansion plans into airports, campuses, and commercial hubs.As Shoucheng’s Executive Director and Co-President Ye Qian stated: “Through interactive and relatable scenarios, we want the public to feel that robots are no longer distant technologies—they’re becoming part of daily life.”From Lab to Market: Accelerating the New Productive ForceWith a dual strategy of equity investment and asset operations, Shoucheng Holdings will continue to drive commercialization of humanoid and embodied robots in education, manufacturing, healthcare, and smart city operations, unlocking the full potential of the next-generation productivity paradigm.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 15, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the “Updated Guidelines”). Etrasimod, an S1P receptor modulator, is recommended for the induction of remission in patients with moderately to severely active UC and for continuation in the maintenance of remission, compared with no treatment after induction of remission. Both recommendations are strong, with a moderate quality of evidence.This milestone underscores the high level of recognition from an internationally respected clinical guideline for the therapeutic value of etrasimod and highlights its potential to address the significant unmet medical needs of UC patients, offering a new treatment option worldwide.The updated guidelines were developed by the American College of Gastroenterology (ACG) including the latest evidence from the past five years. They provide a comprehensive summary of new approaches and advances in the treatment and prevention of complications in UC, with the goal of offering clinicians standardized and evidence-based recommendations to better manage patients with varying degrees of disease severity.The updated guidelines note that, etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P) 1,4,5 receptor modulator for the treatment of moderately to severely active UC. The S1P 1 receptor modulation regulates the trafficking of specific lymphocyte subsets out of the lymph nodes, leaving fewer peripheral immune cells available to traffic to sites of inflammation.The updated guidelines also reference the Phase III ELEVATE UC clinical study for etrasimod (ELEVATE UC 52 and ELEVATE UC 12). Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of etrasimod. Etrasimod has been included in the AGA Living Clinical Practice Guideline on the pharmacological management of moderate-to-severe UC as one of the higher-efficacy medications suggested for first-line use in advanced therapy-naïve patients.Prof. Wu Kaichun at the First Affiliated Hospital of AFMU who is the principal investigator for etrasimod’s Asia clinical trial said “The updated guidelines further emphasize that achieving endoscopic mucosal healing to enable sustained, steroid-free remission is a core treatment goal for patients. This is not only critical for the long-term and safe management of the disease but is also closely tied to improving patients’ quality of life. The strong recommendation of etrasimod for both induction and maintenance therapy in this population reflects the high level of recognition from an internationally authoritative medical authority.”“The inclusion of etrasimod in the 2025 American College of Gastroenterology (ACG) Clinical Guideline for Adult Ulcerative Colitis, with a strong recommendation, is a clear recognition of its clinical efficacy and favorable safety profile. Mucosal healing is a recognized treatment goal in both domestic and international clinical guidelines for UC. Achieving mucosal healing at an early stage can significantly reduce the risk of disease relapse, hospitalization, colectomy, and the development of colorectal cancer.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “In Asia, the number of UC patients continues to rise, while treatment options remain limited, highlighting an urgent need for innovative therapies that balance efficacy, safety, and convenience. In China alone, the UC patient population was estimated at approximately 800,000 in 2024 and is projected to reach 1 million by 2030, placing an increasing burden on the healthcare system.”As a key innovative asset in Everest Medicines’ autoimmune disease portfolio, etrasimod’s inclusion in the clinical guidelines underscores its global therapeutic potential as a new treatment option for UC patients across Asia, including in China. We remain committed to accelerating the regulatory approval process for etrasimod in Mainland China, South Korea, and other Asian markets to enhance patient access and help more individuals achieve higher-quality, longer-lasting disease remission.”As a core product of Everest Medicines, etrasimod has been approved in Singapore, Macao SAR, and Hong Kong SAR, and its NDA has been accepted in South Korea. In December 2024, China’s National Medical Products Administration (NMPA) officially accepted the NDA for VELSIPITY(R). As Everest’s third commercialized product, VELSIPITY(R) has been officially approved by the Guangdong Provincial Medical Products Administration for adult patients with moderately to severely active UC. It is now available at medical institutions designated under the Connect Policy in the Greater Bay Area. Additionally, Everest has launched a factory construction project at its Jiashan site to support local production of VELSIPITY(R). Copyright 2025 ACN Newswire via SeaPRwire.com.

Results Highlights:- Revenue reached US$83.6 million, a year-on-year increase of 5.9%.- Sales volume reached 919,000 units, of which 779,000 units were proprietary products, representing a year-on-year increase of 8.6%.- Profit attributable to owners of the company increased by 5.1% year-on-year to US$19.8 million.- Core operating profit amounted to US$15.1 million, an increase of 11.4% year-on-year.- The Board declared a special dividend of HK15 cents per share to mark the Group’s 25th anniversary.- The Group maintained a sound financial position with cash and bank balances of US$237.1 million as of June 30, 2025 to support potential acquisitions and the construction of new manufacturing facilities.- The Group’s high-quality products have gained widespread recognition worldwide, resulting in revenue growth of 14.0% in the APAC market, 17.0% in the EMEA market, and 20.0% in the US market.- The Group acquired a Taiwan-based distributor in the first half of the year. It also plans to establish direct sales teams in Belgium and the Netherlands in the second half of the year, further strengthening direct presence in APAC and EMEA markets.- Leveraging its global commercialization expertise and extensive distribution network, the Group established strategic partnerships with medical device peers, thereby diversifying its product portfolio and generating additional revenue through cross-selling opportunities.HONG KONG, Aug 15, 2025 - (ACN Newswire via SeaPRwire.com) - OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, today announced its interim results for the six months ended June 30, 2025 (the “Period”), reporting growth in both revenue and net profit despite an uncertain macroeconomic landscape.The Group recorded revenue of US$83.6 million, up 5.9% over the previous year, driven by strong year-on-year growth in the US market, as well as continued contributions from emerging markets in APAC and EMEA. Core operating profit, being profit attributable to the owners of the Company excluding share-based compensation, net tax credit from deferred tax asset in relation to tax losses, and finance income/costs, amounted to US$15.1 million, up by 11.4% year-on-year. Profit attributable to the owners of the Company increased by 5.1% year-on-year to US$19.8 million. Basic earnings per share was US2.40 cents (first half of 2024: US2.28 cents).As of June 30, 2025, the Group maintained a strong financial position with cash and bank balances amounting to US$237.1 million. In light of the Group’s solid financial position and in celebration of the its 25th anniversary, the Board has resolved to declare a special dividend of HK15 cents per ordinary share, demonstrating the Group’s commitment to creating value for its Shareholders. Together with the final dividend of HK10 cents per share for the year ended December 31, 2024 paid on June 16, 2025, Shareholders will receive a total dividend of HK25 cents in 2025.Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “Over the past 25 years, we have continuously invested in innovation and global commercial capabilities, establishing OrbusNeich’s reputation and enabling us to navigate different economic cycles. Despite macroeconomic and geopolitical challenges in the first half of 2025, our global deployment proved resilient. Growth in the US market reflected strong demand for our high-quality products, while our extensive sales network successfully captured growth opportunities in the APAC and EMEA regions. We will continue to sharpen our competitive edge by enhancing brand value through our direct sales market presence, excellent sales support, commitment to innovation, and comprehensive PCI and PTA product portfolio, while advancing safer, more effective solutions for physicians and patients and delivering long-term returns to shareholders.”Global Sales Network and Partnerships Boost Revenue GrowthOrbusNeich has built a sales network spanning over 70 countries and regions, including direct teams in 13 locations and a global distributor network, which proven integral to capturing local opportunities and demand worldwide. APAC revenue rose by 14.0% year-on-year to US$27.3 million during the Period, fueled by growth in Indonesia and increasing adoption of Scoreflex TRIO in Singapore and Malaysia. EMEA revenue grew 17.0% to US$22.4 million, driven by strong proprietary balloon product sales in key direct markets (Germany, France, Spain) and distributor markets (the UK, Slovakia, Czech Republic). Despite tariff disruptions, US revenue increased by 20.0% to US$8.0 million, boosted by a notable surge in sales volume of standard and scoring coronary balloons and peripheral balloons, including the high-priced Scoreflex NC balloon. Revenue from the Japan and PRC markets was US$16.1 million and US$9.7 million, respectively.Leveraging its widely-recognized global commercialization expertise, the Group partnered with peers pursuing international expansion to enrich its product portfolio and drive additional revenue streams. Building on the successful collaboration with SonoScape Medical Corp. involving the distribution of intravascular ultrasound (“IVUS”) products in Hong Kong and Macau last year, the Group has entered into a sole and exclusive distribution agreement with this partner to distribute its IVUS products in Singapore and Malaysia. The collaboration now covers four additional direct European markets (France, Germany, Spain, Switzerland) and six other distributor markets across Europe.Performance-Led Innovation Fuels Market Distinction and Portfolio DiversityAs of June 30, 2025, OrbusNeich had obtained more than 250 granted patents and published patent applications in key jurisdictions worldwide, as well as over 55 approved products.During the Period, the Group made progress in terms of product registrations and clinical trials, including:- Sapphire 3’s US trial progressing smoothly, with patient enrollment set to finish in Q4 2025 to support FDA submission for the CTO indication, distinguishing it from other conventional semi-compliant balloons on the market;- Obtained CE Marks for JADE PLUS and Teleport Glide, PMDA approvals for Teleport Glide and Scoreflex QUAD, FDA approvals for the COREPASS Modular Microcatheter, and NMPA approval for the guiding catheter;- Submitted registration applications for Scoreflex TRIO, Sapphire ULTRA, Sapphire NC ULTRA, Sapphire NC 24, JADE PLUS, Teleport XT and Teleport Glide to the NMPA, and applications for the Vascuaid Aspiration Catheter and GCE Large Lumen to the PMDA.Regarding the Group’s robust product pipeline, the Sapphire PTX paclitaxel drug-coated balloon, in the coronary space, is set to begin clinical trials in Japan near the end of 2025. In the peripheral space, the JADE Score balloon is expected to be submitted for PMDA approval in 2026.The joint venture OrbusNeich P&F also made significant progress in the clinical trials of TricValve in the PRC, with the number of participating sites increased to accelerate patient enrollment. In addition, it has been actively promoting TricValve’s entry into hospitals in the Greater Bay Area (“GBA”) through the Hong Kong & Macau Registered Drugs and Medical Devices Access to GBA Program. The first commercial implantation of TricValve in the Mainland of China was completed in July 2025, marking the achievement of an important milestone.Multi-Region Production Bases Mitigate Evolving Geopolitical RisksAs of June 30, 2025, OrbusNeich’s aggregate annual production capacity was approximately 2.1 million balloons and stents, with production facilities in Shenzhen, the PRC; Hoevelaken, the Netherlands; and Weil am Rhein, Germany. Since acquiring eucatech AG in late 2023, the Group has allocated resources to restore its production capabilities, gradually ramping up output during the Period to supply products for both sales and clinical registries.The Group completed the main structure construction of its largest R&D and production facility in Hangzhou, the PRC, in August 2025, with renovation work expected to begin in the second half of the year. The facility is scheduled to commence operations in 2027, adding an annual production capacity of 2.4 million units.Mr. Chien concluded, “We remain optimistic about the second half of 2025 due to strong momentum in emerging markets, successful proprietary product launches, and strategic partnerships. APAC and EMEA will remain our key growth drivers, with plans to transition selected markets from distributor to direct sales models to enhance revenue and market presence. In Europe, we will establish direct sales teams in Belgium and the Netherlands to expand our footprint. The Japanese market will see renewed momentum through new product launches, while in the PRC market, we will capitalize on policy support to expand product coverage and accelerate commercialization. US shipments are expected to speed up amid easing tariff disputes. Backed by OrbusNeich’s diversified portfolio, strong financial position, and economies of scale, we are well positioned to build a resilient, competitive business that delivers sustainable value to stakeholders.”About OrbusNeich Medical Group Holdings LimitedOrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.For more information, please visit the Group’s official website: https://orbusneich.com/. Copyright 2025 ACN Newswire via SeaPRwire.com.

RAS AL KHAIMAH CITY, UAE, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Ras Al Khaimah International Corporate Centre (RAK ICC) has announced significant amendments to its Foundations Regulations 2019, which took effect on 31 July 2025. The changes represent one of the most substantial updates to the regime since its introduction, reinforcing the UAE's position as a competitive jurisdiction for wealth structuring and long-term asset protection.RAK ICC Foundations are widely recognized for their flexibility, confidentiality, and legal robustness, making them a preferred choice for high-net-worth individuals, entrepreneurs, and family offices, both within the UAE and internationally. These structures are commonly used for succession planning, family governance, and consolidating diverse assets under a single legal entity.The 2025 amendments introduce stronger legal safeguards and improved governance measures which include:Firewall Provisions - Stronger protection from foreign judgments conflicting with RAK ICC Regulations.Three-Year Statute of Limitations - Limits challenges to establishment or asset transfers to three years.Cause of Action Provisions - Creditor fraud claims are limited to the specific asset involved and only if rendering the founder insolvent.Duress and Officer Protections - Nullifies actions taken under foreign legal coercion, preserving internal governance autonomy of a foundation.Strengthened Arbitration Framework - Disputes can be resolved privately with court-level powers.Private Trustee Foundation Provisions - Clarifies asset segregation and fiduciary integrity for property held in trust by a foundation.Assets held within RAK ICC Foundation will now benefit from enhanced firewall provisions, ensuring that foreign judgments conflicting with UAE law cannot be enforced against them. A new three-year limitation period has been established for challenging the formation of a foundation or the transfer of assets into it, providing greater certainty for founders and beneficiaries. The reforms also tighten creditor protection rules by requiring proof of insolvency in fraudulent transfer claims, with liability capped at the value of the disputed asset to prevent overreach into unrelated holdings.In addition, the updated regulations address governance integrity and operational resilience. Officers of a foundation who receive foreign orders inconsistent with RAK ICC law are obligated to disregard them, thereby safeguarding the autonomy of the foundation's decision-making. The framework now explicitly confirms that assets held in trust by a foundation are legally distinct and separate from foundation property, ensuring clear asset segregation. Dispute resolution has also been strengthened, with arbitration provisions expanded to grant tribunals court-like powers, enabling disputes to be resolved efficiently, confidentially, and in line with international best practices.These changes are part of RAK ICC's broader strategy to maintain a forward-looking legal and regulatory environment that meets global standards while catering to the specific needs of its client base. They reflect the jurisdiction's commitment to supporting sophisticated wealth planning strategies that balance control, privacy, and long-term security.By enhancing its Foundations regime, RAK ICC is cementing its position in the UAE as a trusted partner for those seeking secure, adaptable, and internationally compliant solutions for wealth preservation and intergenerational planning.About RAK ICCRas Al Khaimah International Corporate Centre (RAK ICC) is a corporate registry based in Ras Al Khaimah, United Arab Emirates. The organisation provides international business companies and foundations, typically used for private and business structuring, asset consolidation, and succession planning. To date, RAK ICC has incorporated thousands of international companies and supports multi-billion dirhams in structured assets. It serves high-net-worth individuals, entrepreneurs, and businesses seeking flexible and secure solutions for long-term business and wealth management.For media enquiries, contact us at:Phone: +971 7 207 7177Email: info@rakicc.comWebsite: https://www.rakicc.com/contact-us/SOURCE: RAK ICC Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - MMG Limited (“MMG”, stock code: 1208) has today announced its Interim Results with a net profit after tax of US$566.3 million. This represents more than a 600 per cent increase compared to a net profit after tax of US$79.5 million in the first half of 2024.The strong profit growth was primarily driven by increased copper production across all three copper mines, higher market prices for copper, gold, silver and zinc, as well as reduced unit costs at Las Bambas driven by higher copper production.“Over the first half of the year, our business delivered an outstanding operational and financial performance,” said Ivo Zhao, MMG’s CEO. “This result reflects the strength of our portfolio, the capability of our people, and the disciplined execution of our strategy.”Importantly, MMG’s safety performance improved with a total recordable injury frequency (TRIF) of 1.81 per million hours worked in the first half of 2025, an improvement compared to the full-year 2024 TRIF of 2.06. The significant events with energy exchange frequency (SEEEF) for the first half of 2025 remained consistent with the 2024 figure at 0.78 per million hours worked.Operationally, MMG achieved impressive copper sales and significantly improved production across all three of its copper assets, including a strong performance from Las Bambas and the ramp-up at Khoemacau and Kinsevere. Its Australian operations also maintained solid zinc production, despite navigating challenges including weather impacts, equipment reliability and lower grades due to mining sequence.Highlights include:Record first-half results for both EBITDA and EBIT, with EBITDA at US$1,539.9 million, representing a 98 per cent increase compared to the first half of 2024, and EBIT totalling US$1,058.8 million, an increase of 240 per cent over the same period.Net profit after tax was US$566.3 million, including a profit of US$340.0 million attributable to equity holders of the company.A 130 per cent increase in net cash flow from operations, totalling US$1,185.0 million, compared to the first half of 2024. This performance was mainly driven by increased copper sales and higher commodity prices.Balance sheet improvements, with record lows - since the acquisition of Las Bambas - in both net debt and gearing ratio. The Company’s net debt declined by US$903.3 million since the end of 2024, attributed to robust operational cash flow and the early repayment of US$500 million in Khoemacau Joint Venture Group borrowings. Gearing reduced from 41 per cent to 33 per cent over the first half of 2025.Record high total payable copper sales since 2018, reaching 237,651 tonnes in the first half of 2025.Las Bambas produced 210,637 tonnes of copper in copper concentrate in the first half of 2025, marking a 67 per cent increase compared to the same period in 2024. EBITDA reached a record high of US$1,310.5 million, representing a 122 per cent increase compared to the first half of 2024.“MMG’s balance sheet is in great shape – its strongest in 10 years - with debt reduction driven by higher profits and cash generation,” continued Mr Zhao. “Our ambition to become a top 10 global copper producer is within reach and we are well-positioned to achieve this through operational excellence, disciplined capital allocation, and a continued commitment to responsible mining.”Guidance for the year remains unchanged with total production aiming for a high end of 522,000 tonnes of copper and 240,000 tonnes of zinc. Las Bambas is expected to produce up to 400,000 tonnes of copper this year, assuming stable operating conditions and limited external disruptions. MMG is focussed on delivering its cost targets, with Las Bambas and Rosebery favourably adjusting their C1 cost range to reflect improved by-product credits and strong market conditions.The company is working to complete the recent Nickel Brazil acquisition and is confident in the long-term portfolio and growth contribution. MMG remains committed to supporting community development, strong local economies and employment and supplying the critical minerals the world needs for a sustainable future.Read the 2025 Interim Results announcement, watch a short CEO message and download company photos.About MMG Founded in 2009, MMG’s vision is to create a leading international mining company for a low carbon future. The company is headquartered in Melbourne, Australia and Beijing, China and listed on the Hong Kong Stock Exchange (HKEX1208). MMG’s portfolio supports copper, zinc and cobalt production, with soon to be nickel – products that are critical to achieving global decarbonisation and electrification targets. With operations in Australia, Botswana, the Democratic Republic of Congo and Latin America. More info here. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Aug 16, 2025 - (ACN Newswire via SeaPRwire.com) - A 2022 survey from Vanson Bourne revealed that around 91%1 of respondents saw increased demand for automation from business teams. As AI technology evolves, that demand will only grow. AI automations can help organizations work smarter at every level. But how exactly do these workflows function? This article unpacks what AI workflow automation is and how it works behind the scenes.What is AI workflow automation?AI workflow automation is the use of artificial intelligence to automate complex, multi-step tasks that typically require human decision-making. While rule-based automation may rely on rigid instructions, AI automation adapts to data patterns. It learns over time and can flexibly handle unstructured input like emails, documents, or customer requests.AI workflow tools can understand, decide, and act based on context. These tools can help streamline processes and reduce manual effort while improving speed and accuracy.How do AI workflows function?AI workflows function by connecting a series of intelligent tasks or steps to complete a goal from start to finish. The specific tasks can vary depending on the use case. Some workflows may be entirely automated, while some may require human input. Let's take a closer look at some core components that power AI workflows.Machine learning (ML)Machine learning models can make predictions, identify problems, or find patterns. Machine learning has many uses in a workflow including classifying documents or prioritizing tasks. ML acts as the "decision engine", helping automate steps that would otherwise require manual analysis or classification.Natural language processing (NLP)NLP allows AI systems to understand and interpret human language for seamless communication. It's a crucial component in workflows that involve text, speech, or communication. For example, NLP can automatically extract key data from emails or summarize meeting notes. This enables organizations to automate content-heavy tasks without sacrificing understanding or context.Automation triggersAI workflows are usually event-driven. A trigger might be a form submission, a task status update, or an incoming message. Once initiated, the AI workflow executes a sequence of tasks based on logic, conditions, and model predictions. These triggers help organizations respond faster, reduce delays, and eliminate manual intervention.Predictive algorithmsPredictive AI models help forecast future outcomes based on past behavior. These algorithms can be used to detect workflow bottlenecks or even predict them based on past occurrences. Effective predictive models require good data and smart integration. When done right, they can help businesses make smarter, data-informed decisions with minimal human input.Benefits of AI workflowsHere are some of the advantages that AI workflows offer.Increased efficiency: Automations can take on repetitive and time-consuming tasks. This frees up teams to focus on more strategic work.Scalability: AI workflows can process large volumes of data or requests without extra headcount. They make it easier to scale services or operations.Improved accuracy: Trained models and rule-based logic may help reduce the risk of human error.Faster decision-making: AI workflows can analyze data and trigger decisions in real time. This may enable businesses to respond to problems or opportunities faster.From streamlining internal operations to powering real-time customer experiences, AI workflow automation is helping businesses scale their operations at a reduced cost. AI workflows offer a powerful path toward enhanced efficiency.[1] Vanson Bourne - Case studies Salesforce Business Demand for Automation. June 2022. https://www.vansonbourne.com/case-studies/business-demand-for-automation/CONTACT:Sonakshi MurzeManagersonakshi.murze@iquanti.comSOURCE: iQuanti Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest”) today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for VELSIPITY(R) (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC).Building on prior approvals in Singapore, Hong Kong SAR, and Macao SAR, as well as NDA acceptance in South Korea, this marks significant progress in the commercialization of VELSIPITY(R) across Asia. In December 2024, China’s National Medical Products Administration (NMPA) officially accepted the NDA for VELSIPITY(R).As a next-generation selective S1P receptor modulator, once-daily oral etrasimod demonstrates robust efficacy across multiple endpoints, including clinical remission, mucosal healing, endoscopic normalization and histological remission. Its clinical value has been robustly demonstrated in multiple global Phase III studies, including ELEVATE UC 52, ELEVATE UC 12 and ENLIGHT (ES101002) studies.“The NDA acceptance for VELSIPITY(R) in Taiwan, China marks another key progress in our commercialization pathway across Asia. As the number of UC patients in Asia continues to rise, there remains a significant unmet medical need. In China alone, there were approximately 800,000 patients with UC in 2024, and the number is estimated to reach 1 million by 2030. UC patients face the dual challenges of long-term treatment and maintaining quality of life." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “This NDA acceptance underscores the clinical value of VELSIPITY(R). We remain committed to accelerating access to this innovative therapy in Mainland China and other Asian markets, supporting long-term disease management while enhancing patients’ quality of life.”The clinical part submitted to TFDA is mainly based on results from the ELEVATE UC Phase 3 registrational program (ELEVATE UC 52 and ELEVATE UC 12) and the ENLIGHT study (ES101002). The ELEVATE UC Phase 3 registrational program evaluated the safety and efficacy of etrasimod 2 mg once-daily on clinical remission in UC patients with moderately to severely active UC who had previously failed or were intolerant to at least one conventional, biologic, or Janus kinase (JAK) inhibitor therapy. Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of etrasimod.The ENLIGHT study (ES101002) conducted by Everest, is a multicenter, randomized, double-blind and placebo-controlled Phase 3 trial of etrasimod in Asian countries, including China Mainland, China Taiwan and South Korea. This is the largest Phase 3 trial of moderately to severely active ulcerative colitis in Asia completed to date, with 340 eligible subjects randomized to treatment with etrasimod or placebo. The results demonstrate that treatment with etrasimod 2 mg resulted in a clinically meaningful and statistically significant improvement in the primary and all secondary endpoints. These findings provide strong evidence supporting the use of etrasimod in adult Asian patients with moderately to severely active ulcerative colitis.As Everest’s third commercialized product, VELSIPITY(R) has been officially approved by the Guangdong Provincial Medical Products Administration for adult patients with moderately to severely active UC. It is now available at medical institutions designated under the Connect Policy in the Greater Bay Area. Additionally, Everest has launched a factory construction project at its Jiashan site to support local production of VELSIPITY(R). Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Yuexiu Real Estate Investment Trust ("Yuexiu REIT", together with Yuexiu REIT Asset Management Limited, collectively known as the “REIT”; stock code: 405) announced its interim results for the six months ended 30 June 2025.Yuexiu REIT Management Team: Chairman and Non-Executive Director Mr. JIANG Guoxiong (center), Executive Director and Chief Executive Officer Ms. OU Haijing (left), and Chief Financial Officer Mr. KWAN Chi Fai (right)2025 Interim Results Highlights:- Overall operation was stable, with total revenue of RMB966 million (corresponding period of 2024: RMB1,034 million).- As at 30 June 2025, the overall occupancy rate of the properties was 82.2% (corresponding period of 2024: 84.0%).- The average financing cost was 3.33%, representing a decrease of 83 basis points from the beginning of the year. Excluding exchange loss, financing expenses decreased by 13.5% year-on-year.- Interim distribution of approximately RMB0.0333 per unit, equivalent to approximately HK$0.0366. This represents an annualized distribution yield of 8.42%.Guangzhou International Finance Center (GZIFC):- Operating revenue of the GZIFC complex was RMB486 million, accounting for 50.3% of the REIT’s total revenue.- Its office building introduced a Fortune Global 500 company, the occupancy rate was 82.6%, and the renewal rate was 70%.- GZIFC Shopping Mall had a high occupancy rate of 96.4% during the period.- Four Seasons Hotel Guangzhou achieved a 1.1-percentage-point year-on-year increase in average occupancy rate with record room revenue for the period, while Ascott Serviced Apartments GZIFC recorded a 1.8-percentage-point rise in average occupancy and similarly reached historic highs in revenue.Yuexiu Financial Tower:- Yuexiu Financial Tower recorded operating revenue of approximately RMB165 million, representing 17.1% of the REIT’s total revenue. The occupancy rate was 82.1%.- The tenant structure continued to improve, with new introduction of quality tenants such as a Fortune Global 500 company and a futures company with a market value exceeding RMB10 billion.Proactive Management of Financing Risk and Effective Stabilization of Financing Cost- With regard to the short-term loan of RMB530 million and the 5-year syndicated loan of HK$2.1 billion, both due in the first half of 2025, and other loans which are due within the year, the Manager in the first half of 2025 renewed the short-term loan of RMB530 million, obtained offshore loan of RMB1.7 billion and issued dim sum bonds of RMB1 billion for the refinancing and early repayment of the maturing loans so as to ensure effective monitor on the liquidity risk.- The Manager introduced a total of RMB3.23 billion in loans in the first half of 2025 to refinance offshore HKD floating rate loans, taking advantage of the relatively low-cost of RMB financing to proactively adjust the financing structure, thereby minimizing the impact of the interest rate market. At the end of the first half of 2025, the financing interest rate exposure of Yuexiu REIT was approximately 14%, narrowing by 12 percentage points from 26% at the beginning of the year; the average financing cost was 3.33%, representing a decrease of 83 basis points from 4.16% at the beginning of the year; the average interest payment rate for the first half of the year was 3.92%, representing a year-on-year decrease of 64 basis points. Excluding the exchange loss, the finance expenses amounted to approximately RMB402 million, representing a year-on-year decrease of 13.5%.- As at the end of June 2025, Yuexiu REIT had RMB financing of approximately RMB14,795 million, accounting for 72% of total financing (corresponding period of 2024: RMB financing of approximately RMB8,404 million, accounting for 41% of total financing).Mr. JIANG Guoxiong, Chairman and Non-Executive Director of Yuexiu REIT, said, "In the first half of 2025, against the backdrop of global trade volatility and slowing economic growth, China's GDP achieved steady growth of 5.3%, yet corporate expansion remained cautious and slow; retail consumption was weak, and average daily rate of hotel and apartment was under pressure. In order to effectively deal with the headwinds in the industry, we took strategic actions to secure market share by renewing leases in advance, investing in asset appreciation projects to enhance product competitiveness, and effectively stabilizing the fundamentals of operations, which effectively supported the revenue of Yuexiu REIT for the Interim Period. Meanwhile, lower financing cost is beneficial to the distributions.”Guangzhou International Finance Center (GZIFC)GZIFC achieved positive growth in both customer flow and conversion rates through product enhancement and operational optimisation, with a newly contracted area of 13,133 sq.m.. The newly launched 4,235 sq.m. of furnished units recorded an absorption cycle of only about 19 days, with an absorption rate close to 90%. Quality tenants introduced include a Fortune Global 500 company, a leading global shipping company, and a renowned Internet-based culture, sports and entertainment company, taking up more than 2,200 sq.m. in aggregate. In addition, the project recorded a renewed leasing area of 9,099 sq.m. and a renewal rate of 70%, retaining quality tenants including two Fortune Global 500 companies and a foreign consulate. GZIFC was selected as one of the Top 30 companies in the “Performance Index - 2025 Commercial Property Operation Performance” by Guandian.GZIFC Shopping Mall actively created digitalized consumption scenarios, advanced the pilot implementation of the local lifestyle platform “YueXiu Club”, which now covers 12 merchants, while attracting customers through multiple channels such as Dianping and UnionPay QuickPass platforms. Newly contracted area and renewed leasing area totaled 5,734 sq.m., with a renewal rate of 97% and the occupancy rate of 96.4%. During the period, it was announced that China Duty Free Group (CDFG) will set up a store in GZIFC Shopping Mall, which will be the first and currently the only downtown duty-free store in Guangzhou and is expected to open in the third quarter.Room revenue of Four Seasons Hotel Guangzhou and revunue of Ascott Serviced Apartments GZIFC reached a record high for the period, respectively. During the period, the average occupancy rate of Four Seasons Hotel Guangzhou reached 80.1%, representing a year-on-year increase of 1.1 percentage points. The average room rate was RMB2,201, similar to the same period last year. The revenue per available room (RevPAR) was RMB1,762, representing a year-on-year increase of 0.7%. The RevPAR competitive index was 111.7, maintaining a leading market position among luxury hotel competitors. The average occupancy rate of Ascott Serviced Apartments GZIFC reached 92.3%, representing a year-on-year increase of 1.8 percentage point and 9.7 percentage points higher than that of serviced apartment competitors. The average room rate was RMB1,128, similar to the same period last year. The RevPAR was RMB1,041, representing a year-on-year growth of 1.5%. The RevPAR competitive index reached 120.0.Yuexiu Financial TowerDuring the period, Yuexiu Financial Tower recorded a newly contracted area of 7,448 sq.m., including a total of 1,500 sq.m. further took up by seven existing tenants looking for expanded area. 7,089 sq.m. of furnished units were launched, with with an absorption cycle of approximately 38 days and an absorption rate of more than 65%. Quality tenants newly introduced include a Fortune Global 500 company and a futures company with a market value of over RMB10 billion. As certain tenants relocated to their own properties, the project recorded a renewed leasing area of 10,303 sq.m. and a renewal rate of 42%, retaining quality tenants with large leasing areas, including Deloitte, one of the Big Four international accounting firms, and a leading integrated asset management company in China.White Horse BuildingDuring the period, White Horse Building introduced supply chain resources from the Pearl River Delta and recorded a newly contracted area of 3,273 sq.m., with full occupancy on the 1st floor. In the first half of 2025, it welcomed a total of 165 procurement delegations, along with nearly 5,000 purchaser visits, including 23 foreign delegations from France, Vietnam and other countries, and facilitated procurement deals worth RMB140 million. By taking advantage of exhibitions such as the Greater Bay Area International Women’s Wear Expo and the Canton Fair, White Horse Building facilitated tenant transactions. It also successfully launched the cross-border e-commerce platform “White Horse Global E-Channel” and set up a series of courses titled “White Horse Business School Marketing Empowerment Camp” to activate new momentum for tenants’ digital operations.Fortune PlazaDuring the period, the project recorded a newly contracted area of 2,354 sq.m., and introduced quality tenants including several healthcare and elderly care subsidiaries of a Fortune Global 500 integrated financial group. The project recorded a renewed leasing area of 2,924 sq.m. and a renewal rate of 76%, retaining quality tenants including a Fortune Global 500 company, and flexibly adjusted units to match their demand for cost efficiency.City Development PlazaDuring the period, the project recorded a newly contracted area of 7,585 sq.m. and introduced a beauty technology company to enhance the ambience of healthcare business in the building. Retention plans were formulated in light of tenants’ pursuit of cost efficiency, aimed at optimizing product standards to meet tenant needs. The project recorded a renewed leasing area of 2,090 sq.m. and a renewal rate of 68%, retaining tenants including the Guangzhou office of a globally-renowned Contract Research Organisation (CRO).Victory PlazaDuring the period, its anchor tenant, Uniqlo, continued to play a flagship role by launching its C-series products, and hosted the first “A Better Life” campaign of Uniqlo in China, along with gigantic Pokémon installations and A Better Life Music Event, from 28 March to 6 April. Customer flow reached a quarterly peak during the events, driving a 7% year-on-year sales growth in April, and contributing to a 0.3% year-on-year sales growth during the Interim Period. By collaborating with tenants engaged in catering services to capitalize on increased sales with the surge in customer flow, the project drove a year-on-year increase of 0.6% in overall sales during the Interim Period.Shanghai Yue Xiu TowerDuring the period, the project recorded a renewed leasing area of 3,798 sq.m., with a renewal rate of 39%, while securing a newly contracted area of 3,933 sq.m., efficiently making up for the units surrendering ahead of lease expiry. By replacing the energy-saving light tubes in the carpark spaces to enhance brightness, the project enhanced both energy efficiency and service standards, thereby improving tenant satisfaction. As at the end of the Interim Period, the occupancy rate of Shanghai Yue Xiu Tower was 87.2%, representing a year-on-year increase of 2.6 percentage points.Wuhan PropertiesDuring the period, Wuhan Yuexiu Fortune Centre recorded a newly contracted area of 12,395 sq.m., and introduced quality tenants including a member of a leading global automobile group and a diversified professional services company. In addition, it recorded a renewed leasing area of 10,884 sq.m. and a renewal rate of 81%, retaining quality tenants with large leasing areas, including a Fortune Global 500 state-owned enterprise. The business solicitation team optimized the customers’ property visiting experience through partial micro-renovation of units, soft furnishing upgrades and creation of AI model rooms to increase the conversion rate of customers.Starry Victoria Shopping Centre recorded a newly contracted area and renewed leasing area totalling 3,894 sq.m. with a renewal rate of 82% during the period. The project successfully introduced several popular food and beverage brands, including the internet-famous brand “Domino’s” on the 1st floor of Hall A, to attract more family customer groups. The project tapped into nighttime consumption by leveraging the unique appeal of “Joy Garden” on the 4th floor, continuously developing initiatives like “Riverside Starry Night” and “Midnight Diner” to stimulate new sales growth drivers.Hangzhou VictoryHangzhou Victory recorded a newly contracted area of 1,974 sq.m. and introduced a tenant to take up an entire floor during the period. In addition, it recorded a renewed leasing area of 6,083 sq.m. and a renewal rate of 64%, retaining quality tenants including a Fortune Global 500 construction engineering company and the Zhejiang branch of a state-owned enterprise in Shanxi Province.ProspectsThe market generally hopes for further interest rate cuts by the US Federal Reserve in the second half of 2025, though the path and extent remain uncertain. On the other hand, 2025 marks the concluding year of China’s “14th Five-Year Plan”, with policies prioritizing stability, including moderately accommodative monetary policies and “trade-in” consumption subsidy policies aimed at expanding domestic demand to stimulate market vitality. Consequently, the Manager expects the RMB interest rate to remain at a relatively low level. With the accelerated development of new quality productive forces and the advancement of supply-side reforms in China, the Manager expects that new industrial momentum will continue to emerge and business environment will improve. The highly anticipated 15th National Games is scheduled to open in Guangzhou in the second half of 2025, which is expected to boost consumption in shopping malls and demand for hotels and apartments.In the second half of 2025, the Manager will keep abreast of economic development trends and dynamically implement proactive, prudent and flexible leasing strategies, keenly seize potential opportunities, and continuously enhance the market competitiveness of asset portfolio. The Manager will continue to review and make reasonable adjustments to its financing structure depending on expectations of market developments, and introduce low-cost RMB financing through various RMB financing channels to seek more favorable financing costs to offset interest rate risks. Additionally, the Manager will carry out relevant asset appreciation projects as planned, with reasonable planning and phased renovation of the guest rooms at Four Seasons Hotel Guangzhou. By focusing on product enhancement, equipment renewal and safety guarantee, the Manager aims to achieve value preservation and appreciation of the properties and ensure the sound operation of the projects.About Yuexiu Real Estate Investment TrustYuexiu Real Estate Investment Trust ("Yuexiu REIT") was listed on the Hong Kong Stock Exchange of Hong Kong Limited on 21 December 2005 and is the first listed real estate investment trust only investing in properties in the People's Republic of China (the "PRC") in the world. The current property portfolio comprises ten high quality properties, namely Guangzhou International Finance Center, White Horse Building, Fortune Plaza, City Development Plaza, Victory Plaza, Yuexiu Financial Tower in Guangzhou, Yuexiu Tower in Shanghai, Wuhan Properties in Wuhan (including Wuhan Yuexiu Fortune Centre and Starry Victoria Shopping Centre), Victory Business Centre in Hangzhou and Yuexiu Building in Hong Kong, with a total area of ownership of approximately 1.184 million sq.m. All properties are located in the central business district of Guangzhou, Shanghai, Wuhan, Hangzhou and Hong Kong respectively. The categories of the properties include Grade-A offices, commercial complexes, retail business, hotel, serviced apartments and professional clothing market etc.For media enquiries:Strategic Financial Relations LimitedVicky LeeTel: +852 2864 4834Email:sprg_yx@sprg.com.hk Phoebe LeungTel: +852 2114 4172 Maggie ZhangTel: +852 2864 4903 Websitehttp://www.sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC), the five-day (14-18 August) Food Expo, Beauty & Wellness Expo and Home Delights Expo open to the public from today at the Hong Kong Convention and Exhibition Centre. The Food Expo PRO, held concurrently from 14 to 16 August, is open to trade buyers for the first two days and to the public and trade buyers on the final day. For the first time, the Hong Kong International Tea Fair will be open to both industry professionals and the public throughout its three-day duration (14-16 August). The International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM), organised by the Modernized Chinese Medicine International Association (MCMIA) together with the HKTDC and ten scientific research institutions, also take place today and tomorrow (14-15 August).Due to Black Rainstorm Warning Signal, the opening of the fairs was delayed and the first session of the International Conference of the Modernization of Chinese Medicine was livestreamed.The Food Expo, Beauty & Wellness Expo, Home Delights Expo will extend the opening hours to 11pm on 15-17 August. The Food Expo PRO and Hong Kong International Tea Fair will remain open until 6pm today and tomorrow (14 to 15 August) and until 5pm on Saturday (16 August).Margaret Fong, Executive Director of the HKTDC, stated: "The 35th Food Expo celebrates an important milestone this year. The five-in-one mega event plays host to some 1,890 exhibitors from 36 countries and regions, serving as a one-stop destination and a vibrant marketplace for both trade professionals and consumers, where gourmet foods, fine teas, home essentials and beauty products can be found. Meanwhile, Food Expo PRO is dedicated to boosting Hong Kong’s status as a premier business hub for the food industry, not just in Mainland China, but across Asia and the globe. It empowers F&B professionals to explore new opportunities, forge valuable connections, and drive innovation.”Several exhibitors expressed that their special offers will remain unchanged. Among them, Phelix Pun from Ng Fung Hong Limited shared that staff arrived as usual this morning to prepare for the exhibition. They hope that, once the exhibition opens, it will continue to boost their business, with the planned special offers and interactive games proceeding as scheduled. They believe that citizens will continue to turn out enthusiastically to visit and shop.Five themed days create a quality living space1. Shall We Tea' (14 August)Today’s focus is on the variety of Chinese and Western tea beverages. This year, the Hong Kong International Tea Fair opens to the public for all three days for the first time, featuring pavilions from countries and regions such as Fujian, Hubei, Zhejiang, Kenya, and Sri Lanka to promote tea culture. Visitors can sample premium traditional teas like Bai Hao Yin Zhen (Silver Needle tea) (Booth: 5F-F01), one of the finest Chinese white teas, alongside wellness capsule tea (Booth: 5F-F05), and innovative new-style tea beverages from various regions (Booth: 5G-A21). The “Friends of Tea” Zone also offers tea-pairing snacks, tea-infused perfumes and more, offering a blend of traditional and modern tea culture experiences. Visitors can participate in various talks, including "The Legacy and Contemporary Dialogues of Chinese Tea Culture" and "The Beauty of Tea, Where Small Things Reveal Greatness”, as well as activities led by certified water sommeliers and tea masters exploring the diversity of water, decoding the secrets of tea flavours, and delving into the joy of tea appreciation.At the Food Expo, visitors can enjoy premium matcha and hojicha from Kyoto’s century-old Marukyu Koyamaen tea garden, blended with locally made fresh nut butter to create tea-flavoured gelato (Booth: 3B-E10). The Nin Jiom Tea Pairing Lucky Bag (Booth: 1C-A10) includes five functional teas with various health benefits. Additionally, Earl Grey tea infused with bergamot in drip-filter bags (Booth: 1D-A12) offers a refreshing citrus aroma.2. Flavours of Intangible Cultural Heritage (15 August)Despite its small size, Hong Kong boasts over 50 items on its intangible cultural heritage list related to food, showcasing its unique culinary culture. Exhibitors will present tea bags made with 100% Ceylon black tea, ready to brew for an effortless Hong Kong-style milk tea or Yuan Yang (Booth: 5F-F21). Additionally, there’s handmade shrimp paste from Hong Kong’s last remaining licensed salted fish and shrimp paste factory, capturing the authentic flavours of Hong Kong’s fishing village heritage (Booth: 1A-E02).The themed day features a series of activities centered on intangible cultural heritage. At the Home Delights Expo, master artisan Choi Wing-kei will share the story of preserving the traditional craft of floral plaque making, alongside demonstrations of Taiji and Wing Chun martial arts techniques, as well as introductions to the cultural significance of bamboo steamers and bamboo craftsmanship. The Food Expo will showcase demonstrations of making traditional Hakka Sau Fan. The Hong Kong International Tea Fair will host a seminar on "Chiu Chow Kung Fu Tea," exploring the distinctive tea culture of the Chaoshan region.3. Asian Delights (16 August)The day celebrates Asian cuisine and culture, featuring cooking demonstrations of Vietnamese dishes and molecular Thai cuisine, complemented by performances of the traditional Japanese shamisen, K-Pop dance, and a Thai yoga massage experience at the Beauty & Wellness Theatre, immerses visitors in the vibrant essence of Asia.At the Food Expo, the China National Agricultural Pavilion, organised by the Agricultural Trade Promotion Centre, the Ministry of Agriculture and Rural Affairs of Mainland China, will present a thousand agricultural and food products from 13 provinces, such as Korla fragrant pears, Xinjiang safflower seed oil, rainbow trout salmon, Guangdong lychee black tea, Lianzhou mustard greens, Hainan Wuzhishan large-leaf tea, Northeast black soil organic rice, and Yantai apples from the Qilu region.Visitors can explore a range of premium products at the Food Expo PRO. The 100% natural, hand-picked wild pine nut oil from Mongolia (Booth: 5C-G20) is a healthy choice for daily diets. A whisky from Soni Village in Nara Prefecture, renowned for its pristine spring water (Booth: 5B-B06), its smooth taste is perfect for a variety of uses, whether drinking neat, on the rocks, or mixed into a variety of cocktails. The spicy and crispy milk chocolate, made with Sichuan pepper oil, Espelette pepper, and almond paste filling (Booth: 3B-E04), would offer an unforgettable tasting experience.4. Body, Mind, and Soul (17 August)This year, the Beauty & Wellness Expo introduces the new "Scentsation” Zone, featuring over 20 brands showcasing a range of perfumes and aromatherapy products to nurture both mind and body. Making its debut at the expo, Lush (Booth: 3E-D08) presents its popular Deep Sleep Magnesium Massage Bar, designed to enhance sleep quality. In response to the growing opportunities in the silver economy, exhibitors are offering various products and services tailored for seniors. Mannings, participating in the Beauty & Wellness Expo for the first time, will feature a Smart Health Station, offering free health tests to help seniors select the best fit wellness products.The Food Expo, Beauty & Wellness Expo, and Home Delights Expo will host a series of seminars and activities, including hand massage workshops, discussions on the emerging trend of Hong Kong residents seeking cross-border medical care, towel exercise sessions, explorations of ergonomics and the latest treatments for various diseases, and diets to boost immunity. The performance stage will feature various sports demonstrations, such as taekwondo, street dance, and ballroom dancing.5. Taste HK (18 August)In recent years, organic farming has gained popularity, with growing demand for local produce. A cooking demonstration, co-organised by DRAGONS' DEN, the Vegetable Marketing Organization, and the Fish Marketing Organization at the Food Expo, will use local ingredients to create healthy and delicious home-cooked dishes. Additionally, the Home Delights Expo will feature notable products, including a glass-lined insulated handheld cup that won the 2024 Red Dot Product Design Award (Booth: 3F-D20), a water faucet awarded the 2023 Red Dot Design Award (Booth: 3F-B18), and a plug-and-play portable air conditioner that requires no exhaust duct (Booth: 3F-E25).At the Food Expo, visitors can savour a sparkling soda infused with lemon honey, salted plum, and ginger (Booth: 3B-A07), recreating classic Hong Kong flavors. A Kee Wah snack set paired with a cute panda backpack (Booth: 1E-C02) combines iconic treats. At the Food Expo PRO, traditional mooncakes developed by the Hong Kong Polytechnic University’s food team (Booth: 5C-C17) utilise exclusive AkkMore™ fungal fat-replacement technology, blending health with deliciousness.Exploring Halal Products, Coffee, and Food Science OpportunitiesThe 3rd Food Expo PRO and the 35th Food Expo have introduced a Halal food and beverage label since last year to assist exhibitors in expanding into the halal product market. This year, the two expos feature over 120 food suppliers showcasing halal products from around the world, a 20% increase compared to last year. The expo also strengthens collaborations with countries with thriving halal food markets. Group pavilions at the Food Expo PRO include ASEAN countries such as the Philippines, Thailand and Vietnam, enriching the variety of halal exhibits.The Food Expo PRO introduces a new "Coffee Zone" this year, showcasing coffee products, accessories, and machines from various origins. Yunnan Province, China’s leading coffee bean producer, is represented by several Pu’er City companies exhibiting Kunlu Mountain and Jinpaoshan roasted beans and other products. Another highlight, the "Food Science and Technology Zone”, presents alternative and future foods of interest to industry professionals. Today’s Food Tech Symposium explores the development of additive-free foods and clean labeling in Hong Kong. Exhibitors are also targeting the silver economy, showcasing innovative products such as soft-textured mooncakes and cognitive health supplements developed by local exhibitors.21 Prominent Speakers Discuss the Latest Developments in Chinese Medicine (14-15 August)The Modernized Chinese Medicine International Association, together with the HKTDC and ten scientific research institutions, provides industry professionals with the latest insights into Chinese medicine. Themed “The Latest Research Progress in the Prevention and Treatment of Tumors, Inflammation, and Cardiovascular and Cerebrovascular Diseases with Traditional Medicine”, the conference secures 21 prominent speakers, including experts from Hong Kong, Mainland China, and overseas, sharing innovative achievements and trends in the globalisation of Chinese medicine. Conducted in a hybrid format, the conference offers broader opportunities for interaction with speakers. Hong Kong-registered Chinese medicine practitioners can also earn Continuing Medical Education credits by attending the conference.Food Expo Celebrates 35th Edition with Exclusive OffersTo celebrate the 35th Food Expo, free admission tickets are available each day before noon, with 350 each at Halls 3FG and 5FG entrances and redeemable with the designated advertisement. Over 100 promotions are priced at HK$35 or discounted by 65% to tie in with the 35th Food Expo. The “Food Expo 35th Edition – Treasure Hunt” game engages visitors in Hall 3, where they can hunt for ‘treasure’, scan QR codes, answer questions correctly, and redeem gifts. Together with daily lucky draws, prizes are worth over HK$1 million, including kitchenware, furniture, beauty products, gourmet foods, health items; a lucky draw entry is granted for a single transaction of HK$300 or more. The “Smart Bidding” session allows visitors to bid on favourite items starting at 10% of their original price. Visit the “August Happy Buy” promotional website for flash sales and exclusive discounts.Snoopy is celebrating its 75th anniversary this year. The organiser invites visitors to participate in the “Snoopy Hide & Seek” activity at the Home Delights Expo, where they can snap photos with Snoopy and friends for a chance to win special prizes, joining in the festive celebration.Physical ticket sales are unavailable at the venue. E-tickets can be purchased in advance through AlipayHK, Alipay, 01 Space, 7-Eleven, Circle K, Octopus app, or The Club app, or at venue entrances using AlipayHK, Alipay, or Octopus. Discounted “Morning Admission” and “Evening Admission” are offered on select dates.Photo download: http://bit.ly/3Hzud7QThe five exhibitions, including the 35th Food Expo, the 9th Beauty & Wellness Expo, the 11th Home Delights Expo, the 3rd Food Expo PRO, the 16th Hong Kong International Tea Fair, and the International Conference of the Modernization of Chinese Medicine and Health Products, officially opened today.The Food Expo PRO introduces a new "Coffee Zone” this year, showcasing coffee products, accessories, and machines from various originsThe 3rd Food Expo PRO and the 35th Food Expo feature over 120 exhibitors showcasing a variety of halal foods, facilitating procurement for buyersThe Hong Kong International Tea Fair will be open to both industry professionals and the public for the first time, with several regional pavilions, showcasing unique tea cultures and premium tea products from various regions to the public and trade buyersThe Food Expo’s Gourmet Zone features seven themed areas, offering everything from exquisite main courses and craft beverages to delicious dessertsA new “Scentsation” Zone debuts at this year’s Beauty & Wellness Expo and features over 20 perfume and aromatherapy brands, using fragrances to balance the body and mindHome Delights Expo showcases a variety of home tech products, such as Towngas’ steam washing machine with smart stain treatmentOpening dates and times of the exhibitions:DateHKTDC Food Expo PROOpen to trade buyers only: 14-15 August (Thursday to Friday)Open to trade buyers and public: 16 August (Saturday)Hong Kong International Tea FairOpen to trade buyers and public: 14-16 August (Thursday to Saturday)HKTDC Food Expo, HKTDC Beauty & Wellness Expo, HKTDC Home Delights Expo14-18 August (Thursday to Monday)International Conference of the Modernization of Chinese Medicine and Health Products14-15 August (Thursday to Friday)TimeHKTDC Food Expo PRO, Hong Kong International Tea Fair14-15 August: 10:00 am to 6:00 pm16 August: 10:00 am to 5:00 pmHKTDC Food Expo, HKTDC Beauty & Wellness Expo, HKTDC Home Delights Expo14-17 August: 10:00 am to 10:00 pm18 August: 10:00 am to 6:00 pmVenueHong Kong Convention and Exhibition Centre, Wan ChaiAdmission- Food Expo Public Hall, Home Delights Expo, Beauty & Wellness Expo and Hong Kong International Tea Fair 2025 single ticket: HK$30 per person (ticketholders can pay a top-up fee of HK$10 for admission to the Gourmet Zone on the same day)- Food Expo Public Hall and Gourmet Zone, Home Delights Expo, Beauty & Wellness Expo and Hong Kong International Tea Fair 2025 combo tickets: HK$40 per person**HK$36 per person during the pre-sale period from 31 July to 13 August (tickets are available for pre-sale and walk-in at all 7-Eleven and Circle K convenience stores for HK$36 per person.)Remarks: Holders of 16 August single ticket & combo ticket can visit the Food Expo PRO- Morning admission tickets: Entry before noon on 14, 15 and 18 August, Thursday, Friday and Monday, to the Food Expo Public Hall, Home Delights Expo, Beauty & Wellness Expo and Hong Kong International Tea Fair on the same day: HK$10 (pay directly by AlipayHK, Alipay or Octopus card for admission at the hall entrances only)- Night admission tickets: Entry after 6:00 pm on 14 to 17 August, Thursday to Sunday, to the Food Expo Public Hall, Home Delights Expo, Beauty and Wellness Expo on the same day: HK$10 (pay directly by AlipayHK, Alipay or Octopus card for admission at the hall entrances only)- Concessionary price for persons with disabilities: HK$10 (top-up fee for the Gourmet Zone on the same day is HK$10) Note: Persons with disabilities need to present a “Registration Card for Persons with Disabilities”, issued by the Labour and Welfare Bureau (pay directly by AlipayHK, Alipay or Octopus card for admission at the hall entrances only)- Tourist tickets: HK$20 (HK$30 including admission to the Gourmet Zone)Note: Tourists need to present valid travel documents at the fairground to purchase tickets.Free admission is available for children aged three and under and senior citizens aged 65 or above (presenting valid age proof).TicketsE-tickets are available for sale at AlipayHK and Alipay, the 01 Space e-ticketing platform, all 7-11, Circle K convenience stores, Octopus app and The Club app.HKTDC Food Expo PROfoodexpopro.hktdc.comHKTDC Hong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine (ICMCM)icmcm.hktdc.comAugust Happy Buy websiteecoupon.hktdc.com/food/Media EnquiriesOgilvy Public RelationsRex CheukTel : (852) 5618 9908Email : rex.cheuk@ogilvy.comLeanne PokTel : (852) 9379 9694 Email : leanne.pok@ogilvy.comDaisy LeungTel : (852) 9275 7704Email : daisy.leung@ogilvy.comHKTDC’s Communications and Public Affairs DepartmentStanley SoTel : (852) 2584 4049Email : stanley.hp.so@hktdc.orgSerena CheungTel : (852) 2584 4272Email : serena.hm.cheung@hktdc.orgClayton LauwTel : (852) 2584 4472Email : clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Artificial intelligence has many uses in daily life. From personalized shopping suggestions to voice assistants and real-time fraud detection, AI is working behind the scenes to make experiences smoother and more seamless. Behind every smart AI feature is a process that involves two distinct stages: AI training and AI inference. While they're both essential to building intelligent systems, they serve very different purposes and have unique requirements. Let's break down the differences between training and inference.What is AI training?AI training is the process of feeding an AI model large volumes of data, so it learns to recognize patterns and generate the required output.Training generally requires large volumes of labeled or unlabeled data, each of which may facilitate different forms of training.Labeled data: Some projects require a model to make decisions or generate output based on established patterns or correlations. Here, it makes sense to train the model on labeled data using supervised learning techniques.Unlabeled data: Training models on unlabeled data lets them detect new patterns and build an understanding of the relationships between inputs and outputs. This is called unsupervised learning.Think of AI training like teaching a student using flashcards, quizzes, and feedback. During training, the model constantly adjusts internal parameters (often millions or billions of them) to minimize errors and improve accuracy. This phase is computationally intensive and requires specialized hardware like GPUs or TPUs to process large datasets efficiently.For example, training an AI model to recognize objects in images might involve showing it millions of labeled photos of cats, cars, and coffee mugs until it can correctly identify these objects on its own.What is AI inference?Once a model has been trained, it's ready to perform tasks. AI inference is the process of using a trained model to make predictions or decisions on new, unseen data.Inference is typically faster and more lightweight than training. It's used in real-time applications like chatbots, recommendation engines, voice recognition, and edge devices like smartphones or smart cameras. Inference is the test of training. If the output or predictions from your model are inaccurate, you may need to go back to testing.Going back to the earlier example, inference is what happens when you upload a photo to your phone and the AI instantly recognizes your pet as a "cat." The model has been trained to recognize cat images; it just applies what it already knows.Where AI training and inference differThough both stages are part of the same AI lifecycle, they differ significantly in purpose, speed, and system requirements. Here's a closer look at the key differences:ObjectiveTraining aims to teach the AI model by exposing it to data and helping it learn relationships, rules, and patterns.Inference uses the trained model to generate output (such as predictions, classifications, or decisions) based on new data.Time takenTraining can take hours, days, or even weeks, depending on the size of the model and the complexity of the data. It's a resource-heavy, iterative process.Inference happens much faster, often in real time or near real time.Infrastructure needsTraining requires high-performance computing resources such as powerful GPUs or TPUs, and large memory bandwidth. Most training happens in cloud environments or specialized data centers.Inference can often run on lower-powered devices, including edge hardware like mobile phones or IoT devices. Dedicated inference servers or GPU instances may still be needed in some cases.AI training and inference work hand in hand, but they have different goals, requirements, and challenges. Training is about teaching the model, and inference is about putting it to work. Organizations planning AI projects must consider both phases when budgeting, selecting hardware, and choosing infrastructure.CONTACT:Sonakshi MurzeManagersonakshi.murze@iquanti.comSOURCE: OneMain Financial Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Essex Bio-Technology Limited (“Essex” or the “Group”, Stock Code: 1061.HK) is pleased to announce that a Biologics License Application (“BLA”) for EB12-20145P (HLX04-O), a recombinant anti-VEGF humanized monoclonal antibody injection, has recently been accepted by the Centre for Drug Evaluation (“CDE”) of the National Medical Products Administration (“NMPA”) in China. The product is jointly developed by the Group and Shanghai Henlius Biotech, Inc. (“Henlius”, Stock Code: 2696.HK) for the treatment of wet age-related macular degeneration (“wet-AMD”) in China.The phase 3 clinical trial of EB12-20145P (HLX04-O) among Chinese patients (“AURA-1”) has successfully reached the primary endpoint in April this year. AURA-1 is a multi-centre, randomised, double-blind, active-controlled, and non-inferiority phase 3 clinical trial which aimed to compare the efficacy and safety of EB12-20145P (HLX04-O) with that of ranibizumab administered by intravitreal injection (“IVT”) in newly diagnosed wet-AMD patients.In addition to AURA-1, the BLA of which has been validated by the NMPA, an international, multi-centre phase 3 clinical study of EB12-20145P (HLX04-O) in patients with wet-AMD is ongoing successively in several European countries, Australia, the United States, and China (“AURA-2”) with last patient last visit completed by January 2025. Moving forward, Essex will continue to strive for excellence by embracing innovation to develop first-in-class and best-in-class products, providing solutions for Tomorrow’s healthcare problems, Today.About wet-AMDAge-related macular degeneration (“AMD”) is one of the leading causes of visual impairment and blindness in the elderly worldwide [1]. According to the World Health Organization (WHO), about 30 million people have suffered from AMD globally, and about half a million people become blind due to AMD each year [2]. Wet age-related macular degeneration (“wet-AMD”) is characterised by the formation of subretinal choroidal neovascularization (CNV) and is responsible for approximately 90% of cases of AMD-related blindness. Due to an aging population, wet-AMD has become a serious social medical problem and indicated a huge burden of unmet need [3]. With the development of treatment for fundus diseases, anti-VEGF drugs are becoming the first-line therapy for the management of wet-AMD [4], and the efficacy and safety of vitreous injection of bevacizumab for wet-AMD have been verified in multiple clinical studies [5-11].About EssexEssex is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology.These products are marketed and sold through approximately 14,000 hospitals, supported by the Company’s 44 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, Essex maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications.Reference[1] 2020(1).[2] Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004 Nov;82(11):844-51.[3] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2): e106-116.[4] Li X R, Liu J P. Recognition of anti-VEGF therapy base on the mechanism of VEGF in wet age-related macular degeneration[J]. Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology, 2012, 30(4):289-292.[5] Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multi-centre randomized double masked study. BMJ. 2010 Jun 9;340:c2459.[6] Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897-908.[7] Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul;119(7):1399-411.[8] Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar -Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013 Nov;120(11):2300-9.[9] Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group. A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013 Mar;97(3):266-71.[10] Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 Jan;122(1):146-52.[11] Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Peto T, Vingerling JR, Schlingemann RO. Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS One. 2016 May 20;11(5): e0153052. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - SGX Catalist-listed AsiaMedic Limited (the “Company” and, together with its subsidiaries, the “Group”) announced its unaudited financial results for the six months ended 30 June 2025 (“1H2025”), delivering 26% year-on-year revenue growth to S$16.6 million, up from S$13.2 million in 1H2024.This performance was led by the Group’s diagnostic imaging business, which contributed over 60% of total revenue, supported by strong demand at its flagship Shaw Centre clinic and contributions from the newly opened Novena imaging centre.Financial Highlights:Revenue up 26% to S$16.6 million, from S$13.2m in 1H2024, driven by strong growth in diagnostic imaging and steady performance in medical wellness.EBITDA attributable to owners of the Company was maintained at S$1.3 million, reflecting consistent contributions from core businesses, even as the new Novena centre incurred ramp-up losses.Net loss attributable to owners of the Company narrows significantly to S$38,603 from S$104,431 in 1H2024.Cash and cash equivalents stood at S$4.9 million, with an additional S$3.6 million in financial assets, reflecting strong underlying liquidity despite investments into Novena centre.Profitability was significantly affected by the new Novena imaging centre as it remains in its ramp-up phase. However, the Group’s financial performance reflects solid execution of its core business strategy amidst expansion.Mr Arifin Kwek (郭致宾), Chief Executive Officer of AsiaMedic Limited, said, “Our performance in the first half of 2025 reflects the continued strength of our diagnostic imaging business. Shaw Centre remained our primary growth engine with sustained patient volumes, while the newly opened Novena Centre, though still ramping up, has already begun contributing. These investments will further position us as a trusted provider of early detection and preventive care in Singapore.Our health screening and medical wellness segment remained stable, underpinned by the government awarded Grow Well SG programme and steady corporate wellness demand. While the opening of Novena has added to our cost, these are deliberate investments in capacity, technology, and skilled professionals in a key medical geographical location in Singapore, that position us for long term growth.We will continue to build on this foundation, focusing on scaling our imaging and health screening businesses while ensuring we deliver high quality, patient-centred care. With expanded capacity and prudent cost management, AsiaMedic is well placed to capture growth opportunities in Singapore’s healthcare sector.”As Singapore continues to position itself as a regional healthcare hub, AsiaMedic is well-placed to meet growing demand for accessible, high-quality diagnostic and preventive healthcare services. With established centres in Orchard and Novena — two of the country’s key medical precincts — the Group is strategically expanding its reach to serve a broader patient base. This geographic presence, supported by ongoing investments in technology, infrastructure, and clinical talent, positions AsiaMedic to play a meaningful role in advancing Singapore’s preventive care and early detection agenda.This media release should be read in conjunction with the financial statements announced on SGXNet.About AsiaMedic LimitedAsiaMedic Limited together with its subsidiaries (“AsiaMedic” or the “Group”) is a leading healthcare provider in Singapore which provides holistic solutions through integrated application of the latest medical technologies to preventand detect early illnesses to achieve positive experiences and clinical outcomes for patients. AsiaMedic is listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (SGX-ST).The Group is committed to helping clients through practical and personalised solutions delivered with the highestprofessional standards of service and expertise in a timely, safe and consistent manner.With convenient locations at Orchard and Novena, AsiaMedic is a preferred one-stop centre for:Diagnostic imaging and radiology servicesMedical wellness and health screening servicesPrimary healthcare servicesMedical aesthetic services and productsFor more information, please visit www.asiamedic.com.sgFor media and analysts’ queries, please contact:Waterbrooks ConsultantsWayne KooT: (65) 9338 8166 / (65) 8901 9780E: wayne.koo@waterbrooks.com.sg / query@waterbrooks.com.sgThis announcement has been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd. It has not been examinedor approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Pauline Sim (Registered Professional) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 6319 4954. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Following the lifting of the Black Rainstorm Warning Signal at 11:10am, the Food Expo, Beauty & Wellness Expo, Home Delights Expo, Food Expo PRO and Hong Kong International Tea Fair will reopen at 1:10pm.The Food Expo, Beauty & Wellness Expo, Home Delights Expo will be extended and close at 11pm from 15 August to 17 August, allowing public visitors to enjoy shopping in these fairs—with a single ticket. The Food Expo PRO and Hong Kong International Tea Fair will remain open until 6pm today and tomorrow (14 to 15 August) and until 5pm on Saturday (16 August), enabling trade buyers and exhibitors to continue their business discussions.Admission tickets valid for today may be used for entry on any of the remaining fair days.Sessions 2 and 3 of the International Conference of the Modernization of Chinese Medicine afternoon programme will be resumed in a hybrid format.HKTDC Food Expo PROfoodexpopro.hktdc.comHKTDC Hong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine (ICMCM)icmcm.hktdc.comMedia enquiriesOgilvy Public Relations:Rex Cheuk+852 5618 9908rex.cheuk@ogilvy.comDaisy Leung+852 9275 7704daisy.leung@ogilvy.comLeanne Pok+852 9379 9694leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley So+852 2584 4049stanley.hp.so@hktdc.orgSerena Cheung+852 2584 4272serena.hm.cheung@hktdc.orgClayton Lauw+852 2584 4472clayton.y.lauw@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - As the Black Rainstorm Warning Signal was issued at 7:50am, the opening of Food Expo, and the concurrent Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo and Home Delights Expo, will be postponed. The opening ceremony originally scheduled for 10:30am, is cancelled. The International Conference of the Modernization of Chinese Medicine will be accessible via livestream.The organiser will make appropriate arrangements to ensure the safety of those already at the venue and will closely monitor the weather conditions. The organiser will open the Food Expo, Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo and Home Delights Expo two hours after the Black Rainstorm Warning Signal is cancelled.HKTDC Food Expo PROfoodexpopro.hktdc.comHKTDC Hong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine (ICMCM)icmcm.hktdc.comMedia enquiriesOgilvy Public Relations:Rex Cheuk+852 5618 9908rex.cheuk@ogilvy.comDaisy Leung+852 9275 7704daisy.leung@ogilvy.comLeanne Pok+852 9379 9694leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley So+852 2584 4049stanley.hp.so@hktdc.orgSerena Cheung+852 2584 4272serena.hm.cheung@hktdc.orgClayton Lauw+852 2584 4472clayton.y.lauw@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on @hktdc and LinkedIn Copyright 2025 ACN Newswire via SeaPRwire.com.

Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 13, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the resumption of work on the Environmental and Social Impact Assessment ("ESIA") for its 100%-owned Lac Knife flake graphite project located near Fermont, in the province's prolific iron ore mining district.The Company has formally re-engaged IOS Geosciences Inc. ("IOS"), a leading Québec-based geological consulting firm and former general contractor on the ESIA, to complete a total of sixteen (16) technical reports required for submission to Québec's environmental and natural resource authorities. These reports represent a major step in advancing the Lac Knife project toward permitting and the goal of mine construction.The ESIA program, initially launched in 2020, involves multidisciplinary technical evaluations and environmental baseline work conducted across 2020 and 2021. Finalization was delayed due to funding constraints but is now back on track. Report completion is estimated by early 2026, with submissions planned shortly thereafter to the Québec Ministry of Sustainable Development, Environment, and the Fight Against Climate Change ("MDDELCC"), as well as the Ministry of Natural Resources and Forests ("MRNF").The sixteen (16) technical reports in progress cover critical permitting areas, including:Condemnation and pit wall drillingAcid-generating potential analysisGeotechnical drilling and soil mechanicsSoil geochemistry and chemistry baselineLake-bottom geochemical and surface water quality surveysGroundwater habitat assessment and follow-upCaribou habitat assessment and follow-upGeometallurgical and graphite flake characterizationThese comprehensive studies are essential for satisfying Québec's rigorous environmental and social licensing requirements and underscore Focus Graphite's commitment to environmental stewardship and Indigenous engagement through project development.In parallel, Focus has also authorized IOS proceed with geochemical analysis of over 1,000 split and pulverized drill core samples collected from its 2022 exploration drilling program at the Lac Tétépisca ("Tétépisca") graphite project. The samples, targeting the Southwest MOGC and West Limb geophysical (MAG-EM) conductors, will undergo carbon and sulfur determinations at certified laboratories.Upon receipt of assays, IOS will finalize and submit the corresponding technical reports covering 14,900.5 metres of core drilling from 74 holes to the MRNF. An updated Canadian Institute of Mining, Metallurgy and Petroleum ("CIM") and National Instrument ("NI") 43-101 compliant Mineral Resource Estimate ("MRE") for the Manicouagan-Ouest Graphitic Corridor ("MOGC") graphite deposit is anticipated in Fall 2025, which will further define Tétépisca's development potential alongside Lac Knife."Resuming the ESIA is a pivotal milestone that moves us closer to full permitting and our goal of mine development at Lac Knife," said Dean Hanisch, CEO of Focus Graphite. "With most fieldwork and laboratory studies already complete, we're in a strong position to finalize this critical stage efficiently. At the same time, initiating assay work at Tétépisca to support an upgraded mineral resource estimate reflects our commitment to building value across our entire Québec asset base."The Company also announced the grant of incentive stock options as compensation to its directors, officers, employees, and consultants. Options to purchase up to 4,215,000 Common Shares of the Company have been granted at an exercise price of $0.14 per share. The options expire on 13 August, 2030. Additionally, the Company has granted 1,350,000 restricted stock units ("RSUs") to officers, directors, and consultants of the Company under the terms of the Company's restricted share unit and equity incentive plan (the "RSU and EIP Plan"). Each RSU entitles the holder to acquire one common share of the Company after the vesting period in accordance with the Plan.Qualified PersonsThe technical content disclosed in this news release was reviewed and approved by Réjean Girard, P.Geo. (QC), President of IOS Geosciences Inc., a consultant to the Company, and a qualified person as defined under National Instrument NI-43-101.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the completion and submission of the sixteen technical reports required for the Lac Knife Environmental and Social Impact Assessment, the anticipated timeline for ESIA report submission and permitting, the initiation and results of geochemical analyses at the Lac Tétépisca project, the anticipated updated NI 43-101 Mineral Resource Estimate for the Tétépisca deposit, the Company's positioning as a near- and long-term secure supplier of specialty graphite materials, and the potential geopolitical significance of Canadian graphite supply.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262450 Copyright 2025 ACN Newswire via SeaPRwire.com.

Kangji Medical Holdings Limited and Knight Bidco Limited today jointly announced the pre-conditional proposal for the privatisation of Kangji Medical Holdings Limited by way of a scheme of arrangement (the “Proposal”).Proposed privatisation of Kangji Medical Holdings LimitedThe Cancellation Price of HK$9.25 per share represents a 21.7% premium over the closing price on 30 June, 2025, being the Undisturbed Date, a 47.3% premium over the 360-trading day average closing price up to and including the Undisturbed Date, and exceeds the highest closing price as quoted on the Stock Exchange since 2022The proposed privatisation will be effected by way of a scheme of arrangement; the Offeror Concert Parties collectively hold 74.75% shares in the Company; an Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the ProposalThe Proposal presents shareholders with certainty over their ability to monetise their interests in Kangji Medical Holdings Limited, following a period of sustained pressure on trading prices and limited liquidityHONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Aug 12 2025, Kangji Medical Holdings Limited (“Kangji Medical” or the “Company”, Stock Code: 9997.HK) and Knight Bidco Limited (the “Offeror”) today jointly announced a privatisation proposal. The parties intend to implement the privatisation of the Company by way of a scheme of arrangement, with a view to enabling the Company to focus on long-term strategic decisions, such as longer-term business investment in R&D and operations enhancements.Upon completion of the Proposal, the Company will become a wholly-owned subsidiary of the Offeror, and the listing of the Shares will be withdrawn from the Stock Exchange.The Offeror is owned by a consortium comprising Mr. Zhong and Ms. Shentu (the Founders), the TPG Entities, NewQuest V and Al-Rayyan Holding. Rationale for the ProposalDue to the long-term underperformance in the trading prices and trading liquidity of the Shares, the ability of the Company to raise funds from the equity market has been significantly limited. In addition, the Company has to incur administrative, compliance and other listing related costs and expenses for maintaining the listing status. Accordingly, there are limited benefits for the Company to maintain its listing status.In light of intensifying competition in domestic market and ongoing regulatory uncertainties, and in order to achieve sustainable growth, the Company's long-term strategy requires significant investment which could create short-term pressure on the Company’s financial performance. It is anticipated that additional resources need to be allocated to areas including sales and marketing, investment in research, development, and commercialisation, and the Company’s market expansion outside of China.Considering this, and the listing-related costs, there are limited benefits for Kangji Medical to maintain its listing status. In addition, the implementation of the Proposal will alleviate pressure on Kangji Medical’s short-term financial performance, which enables better focus on strategic objectives. It is anticipated that additional resources will need to be allocated for its future sustainable growth.Furthermore, the Proposal provides minority shareholders an attractive opportunity to realise compelling returns amid market volatility, industry and macro uncertainties, and the limited liquidity of the Shares.Knight Bidco Limited’s proposal offers a timely solution to Kangji Medical and its shareholders. Its proposal to privatise Kangji Medical will:(a) reduce Kangji Medical’s administrative, compliance and other listing related costs;(b) relieve Kangji Medical from the pressure associated with short-term performance metrics and enable Kangji Medical to focus on long-term strategic decisions (such as longer-term investment in R&D and operations enhancements which might incur short-term losses); and(c) present shareholders with certainty over their ability to monetise their interests in Kangji Medical at an attractive premium to the undisturbed share price.In summary, the Offeror believes that a take-private transaction is the strategic alternative that provides immediate and most compelling value for all shareholders, while also avoiding exposure to uncertain market conditions.Overview of the ProposalThe proposal sets out a Cancellation Price of HK$9.25 per share, valuing the company at approximately US$1.4 billion on an equity value basis.[1]The Offeror has indicated the Cancellation Price is final and will not be increased further.The Cancellation Price reflects:A 21.7% premium over the closing price on the Undisturbed Date (being 30 June, 2025).A 47.3% premium over the closing price of 360-trading day average price up to and including the Undisturbed Date.An 84.6% premium over the 52-week closing low (HK$5.01) up to and including the Undisturbed Date.A Cancellation Price above the highest closing price as quoted on the Stock Exchange since 2022 (HK$8.66).The Cancellation Price has taken into account, among other things, the recent and historical prices of the Shares traded on the Stock Exchange, publicly available financial information of the Company and with reference to other similar privatisation transactions in Hong Kong in recent years.The Proposal is subject to satisfaction of the Pre-Conditions by the Pre-Condition Long Stop Date (being 31 January, 2026) and the Conditions by the Long Stop Date (being 30 April, 2026). The Company will appoint an independent financial adviser (the “IFA”) to advise the committee of directors who are considered independent for the purposes of the Proposal (the “Independent Directors”) for the purposes of making a recommendation to shareholders in connection with the Proposal. Details of the Proposal including the Independent Directors’ final recommendation on the Proposal and the IFA’s advice will be included in the Scheme Document, expected to be dispatched to shareholders in due course.Scheme MeetingDetails of the Scheme Meeting to be convened will be contained in the Scheme Document which is expected to be dispatched to shareholders in due course.There are several pre-conditions and conditions as set out in the Joint Announcement, including regulatory approvals, shareholders approval and compliance with other legislative requirements.Irrevocable UndertakingAn Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the Proposal. Further details are available in the Joint Announcement.Trading in the Shares of the Company has been suspended on the Stock Exchange since 9:00 a.m. on 18 July, 2025, pending the release of this Announcement. The Company has applied to the Stock Exchange for the resumption of trading of Shares with effect from 9 a.m. on August 13, 2025.J.P. Morgan acted as the exclusive financial advisor to the Offeror.Kangji Medical Holdings LimitedKangji Medical is a medical device group founded in 2004 with headquarters at Hangzhou, Zhejiang Province, China. It was listed at the mainboard of the Stock Exchange of Hong Kong in June 2020 (Stock Code: 9997.HK). The Company specializes in the design, development, manufacture and sale of minimally invasive surgery instruments and accessories (“MISIA”). It strives for the mission of “providing physicians with high-quality products and services, and dedicating to improve people’s health”. The Company offers a comprehensive product portfolio to provide physicians and hospitals one-stop and tailored surgical solutions primarily for four major surgical specialties, including obstetrics and gynecology, general surgery, urology, and thoracic surgery. It is also committed to developing an internationally recognized minimally invasive surgery instruments and accessories platform with global coverage.About Knight Bidco LimitedEach of the Offeror, MidCo and TopCo is a newly incorporated company in the Cayman Islands with limited liability and an investment holding company set up solely for the purposes of implementing the Proposal. As at the date of the announcement, the Offeror is wholly owned by MidCo, which in turn is wholly owned by TopCo. As at the date of this announcement, TopCo is held by the Consortium Members, as to approximately 25.53% by Fortune Spring ZM, approximately 14.47% by Fortune Spring YG, approximately 24.38% by TPG Asia VII, approximately 5.01% by Keyhole, approximately 5.69% by Knight Success, approximately 4.56% by NewQuest V and approximately 20.36% by Al-Rayyan Holding. As at the date of this announcement, save as disclosed in the section headed “Shareholding Structure of the Company” in the Joint Announcement, none of TPG Asia VII, Keyhole, Knight Success, NewQuest V and Al-Rayyan Holding is a Shareholder.Kangji Medical is controlled by Mr. Zhong and his spouse Ms. Shentu who together hold 52.98% of the shares in Kangji Medical. Following the privatisation of Kangji Medical, Mr. Zhong and Ms. Shentu will remain the largest shareholders in the ultimate parent company of the Offeror, holding 40.00% of the shares in TopCo via Fortune Spring ZM and Fortune Spring YG. Further details are available in the Joint Announcement.Each of the Founder Entities is a business company incorporated in the British Virgin Islands.Knight Success is a newly incorporated company in Singapore with limited liability and an investment holding company. Keyhole is an exempted company incorporated in the Cayman Islands with limited liability and an investment holding company. TPG Asia VII is a company incorporated in Singapore with limited liability. Each of Knight Success and Keyhole is either wholly owned or controlled by TPG Asia VII, which is in turn controlled by TPG Asia GenPar VII Advisors, Inc. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).TPG is a leading global alternative asset management firm founded in 1992 with more than US$269 billion of assets under management as of 30 June 2025. For many years, TPG has been investing in transformation, growth, and innovation and aims to build dynamic products and strategies for its investors while also instituting discipline and operational excellence across its investment strategies and performance of its portfolios.NewQuest V is a company incorporated in Singapore with limited liability and an investment holding company. NewQuest V is wholly owned by NewQuest Asia Fund V, L.P., which is in turn controlled by NewQuest Asia Fund V GP Ltd. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).Established in 2011, NewQuest is one of Asia’s leading secondary private equity platforms with the most experienced secondary team in Asia across five offices. Since its founding, NewQuest has focused on working with GPs to create bespoke, tailored solutions to meet liquidity and other strategic needs of private asset owners and their stakeholders. Starting from a strategic partnership forged in 2018, NewQuest became wholly owned by TPG in January 2022.Al-Rayyan Holding is a limited liability company established in 2012 under the regulations of the Qatar Financial Centre Authority in the State of Qatar, and is a 100%-owned indirect subsidiary of QIA, the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term outlook. As at the date of this announcement, Al-Rayyan Holding and its concert parties (other than those who are, or deemed to be, acting in concert with Al-Rayyan Holding solely in connection with the Consortium) are not interested in any Shares.For enquiries, please contact:Kangji Medical Holdings LimitedOfferorMedia contact: Wonderful Sky Financial Group LimitedAngie Li & Jason LaiTel: +852 6150 8598 / +852 9798 0715Email: po@wsfg.hkMedia contact: Brunswick GroupKatelin Stevenson & Tong Li+852 9875 3351 / +86 134 8872 6729TeamKnight@brunswickgroup.com[1] Based on HK$9.25 Cancellation Price per share, 1,207,994,000 shares outstanding, and USD/HKD of 7.85All capitalized terms which are used in this press release but not otherwise defined herein shall have the meanings ascribed to them in the Joint Announcement dated 12 August, 2025. This press release should be read in conjunction with the Joint Announcement, a copy of which is available on https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0812/2025081201338.pdf. Copyright 2025 ACN Newswire via SeaPRwire.com.

ROMEOVILLE, IL, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, has signed an agreement with Syensqo to distribute its Solef® Polyvinylidene Fluoride (PVDF) materials in North America. The agreement expands access to this critical material known for its combination of chemical resistance and flexibility. Solef® PVDF joins a growing list of high-performance materials in Formerra's portfolio designed to advance product development and innovation."With this new agreement, Formerra will be able to support customers across multiple markets with the materials they need to meet demanding application requirements," said Bob Long, Business Development Manager at Formerra. "In addition, this reinforces our commitment to delivering unmatched access, application support, and advanced materials for customers navigating complex performance and regulatory challenges."PVDF is positioned near the top of the performance pyramid for its outstanding chemical and heat resistance. Its inherent flexibility further enhances its suitability for demanding applications in chemical processing, healthcare, and automotive industries. Key properties* include:Heat resistance: Continuous use temperatures up to 150 degrees C (302 degrees F), bursting pressures of up to 139 bar (2,017 psi) at room temperatureChemical purity: Ultra-pure water resistivity, meeting SEMI F-57 specifications for the semiconductor industryBalance of strength and flexibility: Tensile yield strength up to 55 MPa (8,000 psi) with elongation at break up to 100%"We chose Formerra as our distribution partner for Solef® PVDF in North America because of their technical and commercial reach," said Rose Catherin, Sales Director Americas, Channel partners, Distribution and Digital Sales at Syensqo Specialty Polymers. "Their commitment to excellence and long-standing presence in critical markets make them an ideal fit to help expand the availability and use of Solef® PVDF."*As measured by TDSCaption: Formerra Becomes North American Distributor for Syensqo Solef®PVDF.Key Details:Formerra is an authorized distributor of Solef® PVDF from Syensqo in North America.The agreement includes support for high-performance applications across a broad spectrum of industries.PVDF offers excellent chemical resistance, thermal stability, and flexibility.Formerra provides technical guidance and supply chain expertise to support material selection and application development.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2025 ACN Newswire via SeaPRwire.com.

WESTLAKE, OH, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - GEON® Performance Solutions, a global leader in the formulation, development and manufacture of performance polymer solutions, announced today that it received Great Place To Work® (GPTW) certifications for its USA, Canada, Mexico and China locations. Since partnering with GPTW in 2021, GEON's cultural and sustainability vision is to achieve this recognition each year.GPTW Certified GEON is Great Place to Work-Certified in the US, Canada, Mexico and China.GPTW asks employees to quantify and benchmark their experience, workplace culture and leadership behaviors which are proven to deliver market-leading revenue, employee retention and increased innovation."We are thrilled to receive Great Place To Work recognition in all four countries in which we operate for two consecutive years. Great Place To Work companies are evaluated against top employers globally, so this is a testament that our journey to cultural excellence is on the right track," said GEON Chief Executive Officer Tracy Garrison. "We believe leaders in the marketplace must also be leaders in the workplace. To do this, we nurture a positive work culture everywhere we operate while striving to grow in areas that still need improvement."GEON received a 79 percent engagement rating which exceeds the typical company by over 20 percent. GEON's score improved year-over-year in the U.S., Canada and China and held steady in Mexico. The U.S. survey included the full scope of GEON employees, including employees from Foster, LLC which GEON acquired in January of 2025.According to Great Place To Work research, job seekers are 4.5 times more likely to find a great boss at a Certified™ great workplace. Additionally, employees at Certified workplaces are 93 percent more likely to look forward to coming to work and are twice as likely to be paid fairly and have a fair chance at promotion."Like the data show, achieving GPTW certification is not only a reflection of our culture, but it directly impacts our ability to retain good people who are excited to come to work each day," said GEON Chief Human Resources Officer Jerome Beguerie. "This has a direct impact on our customers and their experience with us."About GEON Performance SolutionsGEON® Performance Solutions is a leading innovator in the development of polymer compounding solutions for a broad range of markets including building & infrastructure, consumer, industrial, transportation, and power & communications. With the acquisition of Foster, LLC, GEON has enhanced participation in the high-growth healthcare and medical device industry and builds on a portfolio of highly adaptable vinyl, polyolefin and engineered resin technologies as well as a full-service contract manufacturing business. GEON has approximately 1,200 global associates and 15 world-class manufacturing plants with headquarters in Westlake, Ohio. Learn more at www.geon.com. GEON is a portfolio company of SK Capital Partners.About SK CapitalSK Capital is a transformational private investment firm with a disciplined focus on the specialty materials, ingredients, and life sciences sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital currently has approximately $10 billion in assets under management as of December 31, 2024. For more information, please visit www.skcapitalpartners.com.Contact InformationRenita AndersonVice President, Marketing & Business Developmentrenita.anderson@geon.com678-772-8953SOURCE: GEON Performance Solutions Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - China Lilang Limited (“China Lilang” or the “Company”, together with its subsidiaries, the “Group”; stock code: 1234) today announced its interim results for the six months ended 30 June 2025.Mr. Wang Dong Xing, Chairman and Non-Executive Director of China Lilang, said: “In the first half of 2025, international trade environment became increasingly harsh and complex. During the period, consumer spending in the mainland gradually recovered, but consumers remained cautious about spending on non-essential goods. China Lilang prides a well-differentiated brand matrix that has enabled it to penetrate and have a strong foothold in the menswear market. It appealed to its target customer base through precise product positioning and channel strategies, and launched a number of ‘LILANZ’ and ‘LESS IS MORE’ brand products to meet the needs of the consumer market. In addition, the Group actively deployed omni-channel marketing to enhance the popularity of the Lilang brands and improve the efficiency of online and offline sales channels to boost overall sales and operational competence.”For the six months ended 30 June 2025, the Group’s revenue increased by 7.9% to RMB1,727 million. Among this, revenue of the smart causal collection and other collections urged 31.8%, mainly driven by strong performance in in-store sales of the smart casual collection and new retail business. The core collection recorded a slight decrease of 0.2%, primarily due to one-off revenue deduction resulting from the promotion of DTC business model in Shandong Province and Chongqing City.Gross profit margin increased by 0.2 percentage points year-on-year to 50.2%, mainly due to the increase in average unit price as a result of higher proportion of the direct-to-retail operation in sales revenue. Profit attributable to equity shareholders for the period was RMB242.5 million (2024 Interim: RMB280.1 million). Profit margin attributable to equity shareholders was 14.0%. Earnings per share were RMB20.2 cents.During the period, the Group maintained a healthy financial position with sufficient cash flow. The Board of Directors has recommended payment of an interim dividend of HK11 cents (2024 Interim: HK13 cents) per ordinary share and a special interim dividend of HK5 cents (2024 Interim: HK5 cents) per ordinary share, thereby maintaining a stable payout ratio.The Group diligently advanced its strategic transformation during the period, plus continued to implement its “Multi-brands and Internationalization” development strategy to expand business. The core collection “LILANZ” has continued to consolidate its competitive advantage in the traditional menswear market and successfully amplified its brand awareness and market share. The repurchase and transformation of distribution and agency rights in North-Eastern China and Jiangsu Province were completed last year. During the period, the Group has repurchased the operating rights from distributors in the entire Shandong province and Chongqing city and adopted the DTC model. The "LESS IS MORE" smart casual collection that targets younger consumers continued to operate in a fully direct-to-retail mode. The newly opened stores of the smart casual collection were mainly in South-Western China and Central and Southern China. As at 30 June 2025, there were 2,443 stores for the core collection and 331 stores for the smart casual collection.During the period, the Group continued to optimize its sales channels, opening new stores in shopping malls and outlet stores in prime locations as planned. By incorporating tech-savvy visual aesthetics and youthful, fashionable layouts, the Group has brought the brand’s“Simplicity but not Simple” philosophy to life, thereby enhancing its brand image and driving sales. As at June 30, 2025, the number of stores located in shopping malls rose to 957 (31 December 2024: 933), the store count of outlet stores increased to 121 (31 December 2024: 103), with a total of 2,774 retail stores.The Group completed strategic transformation of its new retail business, upgrading it from an inventory clearance channel into a major new product sales platform, which reported a remarkable 24.6% increase in revenue for the period. While continuing to strengthen its presence on established sales platforms like Tmall, JD.com and TikTok, the Group has also expanded into emerging channels such as Pinduoduo, Wechat Channels and Poizon, creating diversified online sales network all together. It has kept enhancing its e-commerce strategy and leveraged social media platforms such as Xiaohongshu and Weibo to keep releasing high-quality content. This approach has deepened its emotional connection with consumers and presented it with new business opportunities.In terms of“Multi-brands and Internationalization” development strategy, the business of “MUNSINGWEAR” was successfully handed over to the Group in the first half of the year. The Group plans to open its first batch of physical stores in the second half of the year. The Group has opened its first store in Malaysia, which started trial operation in May, marking a significant step in overseas expansion.For the research, development and innovation and brand marketing, the Group is committed to achieving breakthroughs in fabrics, craftsmanship and technologies by pursuing proprietary research and development across its industrial chain, with the goal of enhancing the brand's core competitive advantages. During the period, the Group’s original durable white non-iron shirts, “Water Repellent Down 3.0” and the wash-resistant polo shirts have obtained multiple certifications for their anti-wrinkle, quick-drying, and wash-resistant features, successfully driving sales growth. To step up brand transformation aiming at youth consumers, the Group has harnessed celebrity influence, collaborated with cultural IPs, and employed immersive marketing tactics to engage consumers across various age groups and city tiers.Looking ahead to the second half of 2025, the development of domestic consumer market continues to be challenging. As an industry leader, China Lilang will press on with applying its strengths, following shifts in the consumer market and technological advancement, to promote transformation and to enhance brand influence, achieving sustainable sales and profit growth.In the second half year, the Group will continue to push forward with transformation. It will continue to capitalize on the operational advantages of the DTC model in North- Eastern China, Jiangsu Province, Shandong Province and Chongqing City to achieve healthy expansion, tailoring implementation taking into account the specific conditions of each market to further achieve optimal operational performance. For the smart casual collection, which is operated entirely in the direct-to-retail mode, will have its development foundation strengthened to help maintain its strong development momentum. The Group expects the DTC model to unleash its potential further in the second half year and contribute to sales growth.On the other hand, the Group will continue to leverage the advantages of its sales channel reform, focusing on opening stores in prime locations in premium shopping malls in provincial capitals and prefecture-level cities, and closing the underperforming stores to achieve better overall store performance. At the same time, the Group will prudently expand the layout of outlet stores and increase the number of stores to speed up inventory clearance. The Group aims to achieve a net increase of 50-100 stores in 2025.To achieve both the online and offline development, the Group will accelerate its new retails business by leveraging various platforms to engage young customer groups and strengthen brand market penetration. By increasing brand exposure through multi-dimensional initiatives, the Group aims to increase online sales of new products, expecting a rise to 80% of total e-commerce sales. It will work on optimizing the respond time of its supply chain to meet customers’ needs, via including continuously upgrading its the smart logistics center.With a solid domestic foundation, the Group is confident of accelerating implementation of its “Multi-brands and Internationalization” development strategy. As a key project of its multi-brand strategy, "MUNSINGWEAR" will continue to focus on product development in the second half year to meet the needs of the new middle class for personalized, functional and sustainable fashion. For its overseas business, the Group will open more stores in Malaysia in the second half year to better tap the Malaysian market, as well as actively deploy plans to expand business coverage to other Southeast Asian markets. Furthermore, the Group will promote its brand popularity through collaboration with IPs, as well as enhancing interaction with consumers through precise social media marketing and membership programs to foster customer loyalty and capture bigger market share.Mr. Wang Dong Xing, Chairman of China Lilang, concluded: “While China's consumer market remains challenging, the Group maintains cautious optimism toward the retail sector given the government's implementation of multiple consumption-stimulus measures. The ‘LILANZ’ core collection and the ‘LESS IS MORE’ smart casual collection have both undergone innovative transformation, emerging with clearer positioning. This will enable the Group to enhance precision and efficiency in product development, design, marketing promotion and sales, and ultimately drive the long-term growth. On the other hand, as a steadfast practitioner of sustainable development, the Group has deeply embedded ESG principles into its corporate strategy, consistently driving green innovation and social shared value. During the period, we issued our first independently compiled ESG report titled "Creat a Better Life Together" and formally established an ESG Management Committee, integrating ESG governance into strategic planning and core values – demonstrating our commitment to long-term value creation. Notably, the Group achieved an MSCI ESG rating upgrade to BB, ranking among China's top menswear industry peers. Looking ahead, the Group will continue to reinforce its leadership in the domestic menswear sector and strive to achieve sustainable growth through implementing flexible marketing strategy and continuous innovation, to the ultimate end of generating greater value for shareholders, its employees and customers."About China LilangChina Lilang is one of the leading PRC menswear enterprises. As an integrated fashion enterprise, the Group designs, sources and manufactures high-quality business and casual apparel for men and sells under brands of 'LILANZ' and 'LESS IS MORE' across an extensive distribution network, mainly covering 31 provinces, autonomous regions and municipalities in the PRC. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - Cryofocus Medtech (Shanghai) Co., Ltd. ("Cryofocus" or the "Company," Stock Code: 6922.HK), a global innovator in minimally invasive interventional cryotherapy, last friday announced its unaudited interim results for the six months ended June 30, 2025. The Company demonstrated robust growth momentum and significant operational optimization during the reporting period, with key financial metrics delivering exceptional performance. Notably, its respiratory intervention product portfolio fueled a substantial revenue surge, marking accelerated commercialization progress.Respiratory Intervention Products Emerge as Core Growth Engine, Highlighting Global Competitive EdgeThe Company recorded revenue of RMB51.1 million for the first half of 2025, a 162.4% increase from RMB19.5 million in the same period of 2024, setting a new historical high. This growth was primarily attributable to the strategic focus on respiratory intervention products entering a harvest phase: The Malignant Stenosis Cryoablation System, approved by China’s National Medical Products Administration (NMPA) in March 2025, and the previously commercialized Cryoadhesion System, experienced rapid sales expansion, becoming the dominant revenue drivers. Additionally, the distribution partnership with Boston Scientific’s China affiliate, BSC International Medical Trading (Shanghai) Co., Ltd. (“BSC”), contributed significant incremental revenue from other respiratory intervention products in mainland China.Of particular significance, the Company’s Asthma Cryoablation System received "Breakthrough Medical Device" designation from the U.S. Food and Drug Administration (FDA) – the first such international recognition for a Chinese enterprise in the respiratory interventional cryotherapy field – laying a foundation for global market expansion.Cryofocus has established a highly competitive respiratory intervention portfolio addressing critical indications, including malignant stenosis, benign stenosis, asthma, chronic obstructive pulmonary disease (COPD), peri-pulmonary nodules, chronic cough, and airway tuberculosis. Among these: The Malignant Stenosis Cryoablation System has been successfully commercialized in China; systems for asthma and COPD are in confirmatory clinical trials with expected approvals in 2026; products for cough, tuberculosis, and peri-pulmonary nodules are in various R&D stages; and the Cryoadhesion System (including disposable and re-sterilizable cryoprobes) is approved and marketed. These innovations mainly stem from Cryofocus’s two core technology platforms: unique liquid nitrogen-based cryoablation technology (utilizing liquid nitrogen as the cryogenic energy source) and advanced flexible catheter technology. This integrated platform enables deep low-temperature treatment, precise control, and minimally invasive intervention, offering superior therapeutic efficacy and safety while creating significant technological barriers for competitors.Platform Value Multiplies as Multi-Segment Strategy Accelerates CommercializationCryofocus’s core value extends beyond its respiratory pipeline, underpinned by its distinction as an innovative cryotherapy platform enterprise. Leveraging its liquid nitrogen and flexible catheter technologies, the Company has successfully expanded into multiple high-potential therapeutic areas:In the vascular intervention segment: The Atrial Fibrillation (AF) Cryoablation System (for atrial fibrillation treatment) was commercialized in China in September 2024. The Cryofocus Renal Denervation (Cryo-RDN) System (for hypertension treatment), granted FDA Breakthrough Device designation, is in confirmatory clinical trials. The Pulmonary Hypertension Cryoablation System is currently in the stage of pre-clinical study. The market space for all these related cardiovascular indications is very huge.In the Natural Orifice Transluminal Endoscopic Surgery (NOTES) segment: The respiratory intervention portfolio, as detailed, is rich and leading. The cancer intervention portfolio includes the commercialized Bladder Cryoablation System; the Gastric Cryoablation System and Esophageal Cryospray System are in clinical trials targeting gastric and esophageal cancer markets.In non-cryotherapy products: Commercialized items such as the Pulmonary Nodule Localization Needle and Endoscopic Clip for Anastomosis, alongside pipeline products like the Atrial Fibrillation Pulsed Field Ablation (PFA) System and Anti-Gastroesophageal Reflux System, create complementary synergies.This "one-platform, multi-therapy" model endows Cryofocus with exceptional adaptability for indication expansion and pipeline sustainability. The Company currently boasts a robust portfolio of 23 products and candidates: 14 cryotherapy and 9 non-cryotherapy items, with 11 already commercialized. Such platform-based diversification is rare among single-therapy medical device firms, highlighting substantial long-term growth potential and risk resilience.Strong Financial Performance and Sustained Growth MomentumBeyond the revenue surge driven by respiratory products, Cryofocus’s interim results signal positive ongoing growth. The Company’s technological advantages further translated into financial resilience. Gross profit reached RMB34.3 million for the first half of 2025, up 124.5% year-on-year, with a solid gross profit margin of 67.1%. Enhanced R&D efficiency led to significantly reduced losses. R&D expenses optimized to RMB17.9 million (down 51.9% year-on-year), while the period loss narrowed 51.4% to RMB27.2 million, demonstrating a clear trend toward profitability. Cash reserves increased 40.1% from year-end 2024 to RMB63.7 million, providing a solid foundation for sustained R&D and market expansion.Revenue diversification and quality improved as high-value self-developed products (e.g., Malignant Stenosis Cryoablation System) launched and scaled, complemented by deepening collaboration with BSC. The significant reduction in R&D expenses reflects improved efficiency and reduced consumable needs as products advance, driven by optimized personnel costs and management enhancements. This establishes a sound framework for balancing innovation intensity with cost control.Furthermore, the Company increased investment in sales network development, with selling and distribution expenses rising 174.4% year-on-year to RMB9.2 million, underscoring proactive resource allocation to build marketing teams and promote newly launched products (e.g., Malignant Stenosis Cryoablation System), laying groundwork for future sales scale expansion.Global Peer Benchmark Highlights Valuation PotentialCryofocus’s technological strength in respiratory interventional cryotherapy, particularly in FDA-designated areas like asthma treatment, positions it competitively against global leaders.Benchmarked against Inspire Medical Systems (INSP) (focusing on OSA neurostimulation, differing in indication but similar in respiratory neuro-intervention): Inspire currently holds a market capitalization of US$2.279 billion and a trailing-twelve-month (TTM) P/E ratio of 44.28x. Cryofocus’s Asthma Cryoablation System similarly targets pulmonary vagal nerves via minimally invasive ablation, with an innovative pathway validated by FDA Breakthrough status. Yet, as a diversified platform innovator with a broad pipeline and multiple commercialized products, Cryofocus’s current Hong Kong market valuation (Inspire’s market cap is 12.8x Cryofocus’s) significantly trails Inspire’s.This substantial valuation gap, while influenced by factors such as differing markets (US vs. HK), stages of development (Inspire being profitable and established in the US market), and a single-product focus versus a platform model, nonetheless clearly underscores the significant upside potential in Cryofocus Medtech's current market valuation relative to its technological capabilities, the breadth of its product pipeline, and its potential for globalization breakthroughs. With the advancement of clinical progress for its respiratory intervention products (particularly the Asthma Cryoablation System COPD Cryospray System Peri-Pulmonary Nodule Cryoablation System), the clarification of overseas registration pathways, and the continued high-speed growth in its revenue scale, a market re-rating of its value represents a high-probability event. The current valuation level presents an attractive window of opportunity for investors bullish on the long-term prospects of the minimally-invasive interventional cryotherapy sector and the value inherent in a platform company model.Looking ahead, Cryofocus maintains a clear strategy: rapidly advance clinical development and commercialization of pipeline products; deepen focus on minimally invasive interventional cryotherapy while expanding the portfolio leveraging its core platforms; continuously invest in underlying and supporting technologies; and selectively expand global operations. The Company is steadily transitioning from R&D-driven to a dual-engine model integrating R&D and commercialization, advancing resolutely toward its vision of becoming a "global platform for minimally invasive interventional cryotherapy medical devices." Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - OMS Energy Technologies Inc. ("OMS Energy" or the "Company", stock code: OMSE) and Ministry XR ("Ministry XR"), a leading national institution for AI code governance and technical supervision in Singapore, officially signed a memorandum of understanding on 6 August 2025 to establish an in-depth strategic partnership between two parties. Leveraging AI-driven robotic coding technology and the cutting-edge engineering capabilities possessed by each other, OMS Energy and Ministry XR will jointly promote the intelligent transformation of the traditional energy industry, moving towards a more sustainable development future with high efficiency, low cost and high security.(Left) Mr. How Meng Hock, Chief Executive Officer of OMS Energy and Mr. Andrew Yew, Chief Technology Officer of Ministry XRThis cooperation focuses on the long-term strategic layout of "intelligently reshaping energy", aiming to build a complete ecosystem through three pillars:1.Frontier R&D in AI Robotic CodingOMS Energy and Ministry XR will jointly develop an exclusive AI-driven robotic coding framework tailored for the energy industry, with a focus on breaking through core scenarios such as predictive maintenance, autonomous operation, environmental compliance monitoring, and automation of safety protocols. This technology will significantly reduce human operation errors, eliminate personnel safety risks under different environmental conditions like extreme weather, steep terrain, a space filled with poisonous gas, remote area, etc, improve the uptime of energy infrastructure, and provide technical guarantees for the full-lifecycle inspection and maintenance of critical facilities such as oil and gas pipelines and wellhead systems.2.Commercialization and Large-Scale Market DeploymentTechnology implementation will quickly move from the laboratory to the industrial end: Ministry XR will assist OMS Energy in designing scalable commercialization pathways, including conducting pilot projects, integrating with existing industrial systems, and providing regulatory compliance and certification support. The two parties plan to develop export-grade technologies with global competitiveness, covering the core markets such as Asia-Pacific, the Middle East, and North Africa where OMS Energy currently operate to accelerate the popularization of intelligent solutions in the energy industry.3.Academic and Innovation Ecosystem CollaborationBuilding on OMS Energy's long-term R&D cooperation with institutions such as the A*Star Singapore Institute of Manufacturing Technology (SIMTech), OMS Energy and Ministry XR will jointly establish an "AI-Robotics Innovation Laboratory" with top academic institutions. They will develop professional courses, establish talent delivery channels, promote the direct transformation of scientific research achievements into industrial applications, and form a closed loop of "industry-research-application".Shared Vision: Let Intelligence and ESG Concepts become Industry StandardsMr. How Meng Hock, Chief Executive Officer of OMS Energy, added: "OMS Energy has been deeply engaged in the oil and gas engineering field for nearly 50 years, with 11 manufacturing bases in 6 countries and a professional team of over 600 people. Our core products, OCTG (Oil Country Tubular Goods) and SWS (Surface Wellhead Systems) have sold to over 200 high-quality customers worldwide. This cooperation with Ministry XR will accelerate our business expansion into a 'full-lifecycle pipeline inspection and maintenance service sector in oilfield and urban water supply and wastewater industry', making AI robotics technology the core engine for cost reduction, efficiency improvement, environmental risk elimination and green development in the energy industry. Safety operation is paramount in the oil and gas industry due to the inherent risks associated with the work. AI robotics technology will significantly reduce the risks involved in daily operations in oil and gas projects, especially in extreme climates and harsh geographical environments, and further ensure the sustainability, safety, and efficiency of operations."Mr. Andrew Yew, Chief Technology Officer of Ministry XR stated at the signing ceremony: "As a leading national institution for AI code governance and technical supervision in Singapore, we will participate in the full-lifecycle of OMS Energy projects, providing full-dimensional support from technology selection to strategic implementation. This cooperation is not only a response to the digital transformation of the energy industry but also a proactive layout to lead global energy technology standards."About OMS Energy Technologies Inc.OMS Energy Technologies Inc. is a seasoned engineering and technology enterprise in the upstream oil and gas development sector, specializing in the design, certification, and manufacturing of precision engineering systems. Its core products include OCTG (Oil Country Tubular Goods), SWS (Surface Wellhead Systems), and specialized connectors, while also providing value-added services such as advanced threading processing and pipeline inspection and maintenance. With business covering regions including Asia-Pacific, the Middle East, North Africa, and West Africa, and backed by authoritative certifications such as ISO 9001 and API Q1 as well as stable financial performance, the Company has become a trusted partner in the global energy industry.About Ministry XRMinistry XR is a leading national institution for AI code governance and technical supervision in Singapore, dedicated to promoting the standardized application and industrial implementation of AI and robotics technologies. It has profound industry know-how in fields such as technical standard formulation and evaluation of global cutting-edge technologies, providing strategic guidance and technical support for the digital transformation of key industries.This press release is issued by Messis Global on behalf of OMS Energy Technologies Inc.For investor and media inquiriesEmail: pr@messis-global.com Copyright 2025 ACN Newswire via SeaPRwire.com.

TransNusa Increases Flight Options For Two Routes From ManadoPT TransNusa Aviation Mandiri converts two chartered flights from Manado to scheduled commercial flightsTickets sale for Manado to Shanghai and Manado to Shenzhen started on July 29, 2025TransNusa continuously expands international route and starts strengthening Manado base in IndonesiaJAKARTA, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - FOCUSING on organic growth, TransNusa converts two charter flight routes between Manado and Shanghai as well as Manado and Shenzhen to scheduled commercial routes, starting 8 September and 2 October, respectively.TransNusa Group Chief Executive Officer, Datuk Bernard Francis said while the Manado-Shenzhen scheduled commercial flight is direct, the Manado-Shanghai flight plan has a stop-over of between 30 to 35 minutes at the Clark International Airport.“Our main priority and focus is to create new exciting routes for our passengers and offer seamless and fast travels, whether through direct routes or transits routes.” Datuk Francis said, explaining that the Manado-Clark-Shenzhen route is very popular among tourists.“With the launch of these new commercial routes, we hope to provide tourists from Manado and China additional options to travel,” Datuk Francis said, adding that TransNusa will also provide its passengers with options to visit other major tourist destinations from Manado, such as Bali, also known as Indonesia’s Island of Gods.Details of the new RoutesFrom October 2, TransNusa will be operating three flights a week from Manado’s Sam Ratulangi International Airport to Shenzhen Bao’an International Airport. The TransNusa flight, 8B 175, will depart Manado at 21.10pm and arrive at the Shenzhen Bao’an International Airport at 01.00am while TransNusa flight, 8B 176, will depart Shenzhen Bao’an International Airport at 02.00am and arrive in Manado at 05.50am.TransNusa will be operating the Manado-Shenzhen route three times weekly. The Manado-Shenzhen route scheduled commercial flights are on Tuesday, Thursday and Saturday while the Shenzhen-Manado route scheduled commercial flights will be on Wednesday, Friday and Sunday.TransNusa’s scheduled Manado-Shenzhen flight ticket price starts from as low as IDR3.499.000, CNY1.525 and USD226 while it’s schedule flight from Manado to Shanghai ticket price starts from as low as IDR3.988.000, CNY1.688 and USD257. TransNusa tickets are available for purchase at transnusa.co.id and all other main online travel agent platforms worldwide.Meanwhile, the TransNusa flight, 8B 101, from Manado will depart at 14.00pm and arrive at the Clark International Airport at 16.40pm. The flight will depart Clark International Airport at 17.15pm and arrive at the Shanghai Pudong International Airport at 20.55pm. The flight, 8B 102, will depart the Shanghai Pudong International Airport at 23.05pm and arrive at Clark International Airport at 02.30am. The TransNusa 8B 102, will depart Clark International Airport at 03.00am and arrive at Manado’s Sam Ratulangi International Airport at 05.30am.Datuk Bernard said that TransNusa will operate the six hours 50 minutes scheduled commercial flight route 3 times week. TransNusa’s scheduled commercial flight from Manado will depart on Monday, Wednesday, and Friday.For both the newly introduced scheduled commercial flights, Datuk Bernard said TransNusa will be utilizing its C909 jet airliner, which has only 95 seats, to ensure that passengers travel with comfort.Datuk Bernard Francis…TransNusa offers new flight options for its passengersBrief History On TransNusaTransNusa, which had to close business due to the Covid-19 pandemic was injected with new shareholders and management team in 2022. The airline opened its doors for business in October and within six months, in April 2023, launched its first international flight from Jakarta to Kuala Lumpur, Malaysia.After which, under the new leadership of Datuk Francis, and the new management team, the airline successfully launched three more new international routes by the end of 2023. In 2024, the airline continued growing its international and domestic route and at the same time recording historical firsts that also became a significant industry first for the Indonesian aviation industry. Since April 2023, TransNusa has been making headlines in Malaysia, Singapore, China and around the world with news of being the first airline in Indonesia and the world to develop and introduce a new domestic route connecting Bali and diving haven, Manado. TransNusa also became the second Indonesian airline to receive approval to fly to China and provided Indonesians with more pricing and route options to China.TransNusa’s aggressive international growth strategy combined with its domestic business operations approach has enabled the airline to be the fastest growing airline in South East Asia.About TransNusaTransNusa Airline, is a Premium Service Carrier. After the take-over, in February 2024, the airline rebranded itself from being a Low-Cost Carrier to a Premium Service Carrier in line with its upgraded aircrafts that offers better comfort as well as based on the flexibility and quality of the services offered.TransNusa, which received its AOC certification on 9th September 2022, launch its first three A320 operations on 6th October, 14th October and 12th December, 2022. In 2023, TransNusa introduced a new business model making it the first Premium Service Carrier in the Asia Pacific region. TransNusa introduced its first international flight on 14th April, 2023. The airline is currently has bases in Jakarta, Bali and Manado.The airline currently flies from Jakarta to Yogyakarta, Bali, Kuala Lumpur, Malaysia, Subang, Malaysia and Guangzhou, China. It also flies from Bali to Jakarta and Manado. TransNusa will be launching its scheduled Bali to Perth route on March 20th and its Bali to Guangzhou route on April13th. TransNusa made history when it became the second Indonesian airline to fly to China and the first Indonesian airline to launch a Premium Service Carrier business model.Passengers can book their flights on the TransNusa website (www.transnusa.co.id), through authorized travel agents in Singapore, Malaysia and Indonesia, or by contacting the airline's customer service centre at, +62216310888. For the Singaporean market, passengers can contact TransNusa’s General Sales Agent, Chariot Travels Pte Ltd, at +65 86602719 for assistance.TransNusa’s Primary Media Contact:Trina Thomas Rajtrina@myqaseh.org+60124992672 (watsapp) Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC) organised a delegation to Hanoi, Vietnam from 5 to 7 August to promote Hong Kong’s professional services and assist Hong Kong professional service providers in exploring business opportunities.As Hong Kong's sixth-largest trading partner and the second largest among ASEAN members, Vietnam has steadily strengthened trade and economic relations with Hong Kong. The delegation aims at further deepening bilateral business ties and introducing Hong Kong's professional services to local businesses there.The delegation, co-led by Patrick Lau, HKTDC Deputy Executive Director, and Rimsky Yuen, Chairman of the HKTDC Professional Services Committee Advisory Committee, comprised 19 Hong Kong professionals from various sectors, including accounting, legal, consulting and corporate services.During the visit, delegate Tim Koo, Director, Normsun Advisory Services Limited, signed a memorandum of understanding (MoU) with the Institute of Trade and Economics of Vietnam, reflecting a commitment by both sides to strengthen cooperation.Meetings with Vietnam’s government bodies, industry associations and large local enterprises – such as the Foreign Investment Agency under Ministry of Finance, Kinh Bac Group, National Innovation Center, The Association of Chartered Certified Accountants Vietnam, The Vietnam Association of Certified Public Accountants, Vietnam Bank’s Association, Vietnam International Arbitration Centre and VMO Holdings – provided a plethora of opportunities for Hong Kong delegates to explore cooperation opportunities with their Vietnamese counterparts. One of the mission highlights, which was the lunch seminar co-hosted by the HKTDC and Vietnam Chamber of Commerce and Industry, successfully promoted Hong Kong’s role as a regional centre for professional services and risk management. Attracting over 120 Vietnamese business representatives and professionals, it encouraged local enterprises to collaborate with Hong Kong service providers when expanding their business or managing risks.At the lunch seminar, Dr Lau said: "This mission is a part of the HKTDC's new Hong Kong Professionals Plus campaign. We hope to tell the stories of Hong Kong through business delegations and visits as well as promote the strengths of Hong Kong's professional services sector, while at the same time assist them to better understand the latest developments in the ASEAN markets and to seize business opportunities."Mr Yuen stated: "As an international financial centre and a regional hub for professional services, Hong Kong possesses top-tier talents offering world-class legal, financial and consulting services. With extensive experience in facilitating cross-border investments and fund-raising over the years, Hong Kong can meet the development needs of Vietnamese enterprises and assist investors from other countries in seizing opportunities in Vietnam."The HKTDC regularly organises business missions across industries. It will continue to conduct outreach activities to promote the advantages of Hong Kong’s professional services, while helping service providers seize more overseas collaboration opportunities.Photo Download: http://bit.ly/4fu1HBjPatrick Lau, HKTDC Deputy Executive Director (third left, front row), and Rimsky Yuen, Chairman of the HKTDC Professional Services Committee Advisory Committee (fourth left, front row), co-led a delegation to Hanoi, Vietnam, comprising 19 delegates from the professional services sectorTim Koo, Director, Normsun Advisory Services Limited (second right) signed a memorandum of understanding (MoU) with the Institute of Trade and Economics of VietnamA highlight of the mission was the lunch seminar co-hosted by the HKTDC and Vietnam Chamber of Commerce and Industry, which attracted over 120 business representatives and professionals from VietnamPatrick Lau, HKTDC Deputy Executive Director, delivered remarks at the lunch seminarRimsky Yuen, Chairman of the HKTDC Professional Services Committee Advisory Committee, spoke at the lunch seminarMedia enquiriesHKTDC’s Communication & Public Affairs Department:Johnny Tsui Tel: (852) 2584 4395 Email: johnny.cy.tsui@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.

DUBAI, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - 31 Concept (31C), an emerging leader in network intelligence and cybersecurity innovation, today announced it will unveil its first patent-pending technology at ISS Asia 2025 in Singapore. The breakthrough, developed entirely within the company's 31 Concept Research Lab, marks a major milestone for the startup, which is stepping out of stealth mode after just seven months of intense development.31 Concept's Innovation PatentedThe 31 Concept Research Lab serves as the company's innovation engine, uniting world-class experts in deep packet inspection, AI-driven analytics, cybersecurity, and advanced networking. With decades of combined experience from projects spanning telecom, military, and national infrastructure, the lab's team operates at the intersection of applied research and practical deployment, delivering solutions designed to solve real-world challenges at scale."Our patent-pending technology is the direct result of the unique expertise and relentless drive inside our Research Lab," said Misha Hanin, CEO and Co-Founder of 31C. "We built this in record time without compromising on quality or innovation. This is just the first step in a series of breakthroughs we intend to bring to the market."ISS Asia, recognized as one of the most important professional conferences in the world for intelligence, security, and law enforcement technologies, will provide the global stage for the debut. The event draws leaders from government, telecom, and private industry, making it the perfect venue for 31C's first public presentation."The speed at which the 31 Concept Research Lab turned a concept into a patent-pending reality shows the strength of our people and our process," added Boriss Heismann, CTO of 31C. "This is technology designed to address the most pressing needs in network visibility, security, and performance - and to do it in ways the industry has not seen before."The company's presentation at ISS Asia 2025 will highlight the capabilities of the new platform, detail the patent-pending elements, and outline the roadmap for further innovations currently in development.About 31C31 Concept is a technology company focused on next-generation data intelligence platforms for telecom providers, governments, and regulated industries. Its flagship R&D division, the 31 Concept Research Lab, develops breakthrough technologies in network intelligence, cybersecurity, and AI-driven analytics.Contact InformationMisha HaninCEOmisha.hanin@31c.ioSOURCE: 31 ConceptRelated Images Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - On August 8, the first batch of data center REITs—Nanfang Range Technology Data Center REIT and Nanfang Wanguo Data Center REIT—officially debuted on the Shanghai and Shenzhen stock exchanges, both hitting the daily price limit on their first day of trading, closing at RMB 5.850 and RMB 3.9, respectively. Their strong performance marked the official entry of the REITs market into the "tech new infrastructure" arena and underscored the important role of industrial capital in driving the securitization of computing power infrastructure.As a key investor in both projects, Shoucheng Holdings Limited (0697.HK) has once again found itself in the spotlight. Through its wholly-owned subsidiary, Beijing Shouyuan Xinrong Investment Co., Ltd., and the Beijing Pingzhun Infrastructure Real Estate Investment Fund under its management, Shoucheng Holdings invested in both Nanfang Wanguo Data Center REIT and Nanfang Range Technology Data Center REIT. This represents not only another precise move in the data center sector but also the latest step in Shoucheng’s broader REITs market strategy.Tapping into the “Computing Power Base” to Capture Digital Economy GrowthAccording to public information, the Nanfang Wanguo Data Center REIT is backed by the Guojin Data Cloud Computing Center in Huaqiao, Kunshan, with 4,192 racks; the Nanfang Range Technology Data Center REIT is backed by the A-18 Data Center at Runze (Langfang) International Information Port, located in the Beijing-Tianjin-Hebei National Computing Hub, with 5,897 racks and an occupancy rate exceeding 99%. Both assets are core regional computing power resources, playing a vital role in supporting 5G, artificial intelligence, and big data applications.Industry experts note that the launch of data center REITs marks the first time that public REITs in China have covered the technology innovation infrastructure segment, facilitating more efficient allocation of computing resources and enhancing the capital market’s ability to serve the digital economy.Full-Chain Deployment: Building a Closed-Loop REITs EcosystemShoucheng’s involvement in the REITs market has long gone beyond single investments. Since becoming one of the largest strategic investors in China’s inaugural public REITs in 2021, the company has built a complete ecosystem covering “Pre-REITs industrial fund incubation — platform operations — public REITs exit — strategic placement investment.”Currently, Shoucheng’s REITs fund management scale exceeds RMB 30 billion, with investments spanning transportation hubs, urban renewal, green energy, and data centers. In 2025 alone, the company has invested in the Sunlon REIT and the Huadian REIT, and through the Beijing Pingzhun Infrastructure Real Estate Investment Fund, partnered with China Life Investment and Caixin Life Insurance to launch a RMB 10 billion Pingzhun Infrastructure Fund, further strengthening its position as a leading industrial capital player in the REITs market.Industrial Capital Advantage: Driving Sustainable Market DevelopmentAs an industrial capital investor, Shoucheng Holdings not only provides funding but also leverages its expertise in asset management, operations, and integration of intelligent infrastructure to enhance both the operational efficiency and long-term value of underlying assets. This “capital + operations” dual empowerment model differentiates the company from pure financial investors in the REITs market.Analysts believe that with the ongoing expansion of China’s public REITs market and the acceleration of securitization in emerging infrastructure such as data centers, Shoucheng Holdings is well-positioned to benefit from the convergence of “new tech infrastructure + REITs” and to consolidate its leadership in the sector.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 6, 2025 - (ACN Newswire via SeaPRwire.com) - 5 August, The well-known dual-listed beauty and skincare group in Asia, Natural Beauty Bio-Technology Limited ("Natural Beauty"), together with its subsidiaries (the "Group"; Hong Kong stock code: 00157), today announced its interim results for the six months ended 30 June 2025 (the "Review Period"). The Group's turnover and profit for the Review Period soared by nearly 70% to over HK$260 million and 136% to HK$11 million, respectively. A good number of its core indicators for the period also reached record highs, evidencing the strong development resilience and growth potential of the Group in the beauty and skincare sector.Mainland China, which is the core market of the Group, recorded turnover HK$220 million in the first half of 2025, up 101% year-on-year, and has thus become the main driving force of the Group’s overall performance growth. In terms of channels, the franchise model performed particularly well, contributing turnover of HK$200 million, a 115% increase year-on-year. In the Review Period, 237 new franchise stores were added, a leap of 88%. The rapidly expanding store network has given the segment solid support for turnover growth. Turnover from self-owned channels (including counters) climbed by 112% to HK$13 million, reflecting the success of its refined retail operations. In addition, the turnover of the health supplements segment also grew by 110%, to HK$28 million, a testament to the success of the Group’s “Holistic Health” strategy.Dr. Lei Chien, Chairman and Executive Director of Natural Beauty, said, "The Group's ‘AI Technology, Beauty Industry, Holistic Health’ strategy has brought remarkable results and enabled us to transform our brand. In AI technology development, our strategic partnership with Spain's INDIBA has enabled the integration of their cutting-edge devices with our proprietary formulations, resulting in the co-created White Moonlight product series. By combining advanced international technology with our proprietary skincare solutions, we've transformed the series into a market bestseller - clear validation of this collaborative model's effectiveness.Mr. CHENG Chi-Chung, who has just completed his first year as the Group CEO, has led the team in strategically expanding the beauty ecosystem by introducing an agent-based store expansion and partnership model, driving rapid growth in the franchising channel. He said:” We have established a comprehensive 'Standardized Operations System + End-to-End Support Framework', enabling franchisees to replicate successful models efficiently. This system has facilitated the successful launch of 237 new stores in the first half of this year, all achieving strong business growth.Beyond the dual growth in cosmetics and AI devices, our "Total Wellness" strategy for health supplements delivered outstanding results - generating HK$28 million in revenue with nearly 110% year-on-year growth. The success stems from two key factors: firstly, the products, which closely align with consumers health demand of ‘internal and external nutrition’, are made with premium ingredients sourced globally and technically supported by cross-strait R&D centers apt in delivering high-quality nutritional solutions, and secondly, integrating with ‘Holistic Health’ scenarios, health supplements are promoted alongside skincare services to create closed-loop consumption. That confirms the strong market recognition we enjoy for our comprehensive ‘skincare + health management’ solutions.”Looking ahead, benefiting from consumption rebounding and industry upgrade, the Group will, with its “AI Technology, Beauty Industry, Holistic Health" strategy at the core, push forward in two key directions: continue to integrate industrial chain resources to speed up digital transformation across channels, and use big data to accurately capture demand and build a “demand—R&D—channels” closed-loop system to reinforce the market leadership.Photo caption:Nature Beauty OutletAbout Natural Beauty Bio-Technology Limited (Hong Kong stock code:00157)A China’s leading listed beauty and skincare brand established in 1972, has championed its core philosophy of "Natural Beauty Is True Beauty" for 54 years. Driven by its "AI Technology, Beauty Industry, Holistic Health" integrated strategy, the brand operates a global network of over 2,000 outlets. As a Chinese-origin transnational biotech pioneer, Natural Beauty continues to propel innovation in the cosmetics and skincare sector.Media enquiriesStrategic Financial Relations LimitedMandy GoTel: +852 2864 4812Email: mandy.go@sprg.com.hk Maggie ZhangTel: +852 2114 4903Email: maggie.zhang@sprg.com.hk Website:http://www.sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.